Discovery and characterization of Cas13b, a differentially regulated RNA-targeting CRISPR system by Smargon, Aaron Andrew
Discovery and Characterization of Cas13b, a
Differentially Regulated RNA-targeting CRISPR
System
by
Aaron Andrew Smargon
A.B., Princeton University (2011)
S.M., Massachusetts Institute of Technology (2016)
Submitted to the Department of Electrical Engineering and Computer
Science
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Electrical Engineering and Computer Science
at the
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
February 2018
c○ Massachusetts Institute of Technology 2018. All rights reserved.
Author . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Department of Electrical Engineering and Computer Science
January 10, 2018
Certified by. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Feng Zhang
Associate Professor, Brain and Cognitive Sciences and Biological
Engineering
Thesis Supervisor
Accepted by . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leslie A. Kolodziejski
Professor, Electrical Engineering and Computer Science
Chair, Department Committee on Graduate Students
2
Discovery and Characterization of Cas13b, a Differentially
Regulated RNA-targeting CRISPR System
by
Aaron Andrew Smargon
Submitted to the Department of Electrical Engineering and Computer Science
on January 10, 2018, in partial fulfillment of the
requirements for the degree of
Doctor of Philosophy in Electrical Engineering and Computer Science
Abstract
RNA plays a significant role in human biology and disease, not only as messenger
RNA encoding proteins but also as noncoding RNA regulating DNA, proteins, and
other RNA species. Until recently, it has been challenging to target RNA in a simple,
efficient manner. CRISPR-Cas (clustered regularly interspaced short palindromic
repeats and CRISPR-associated proteins) systems, which confer adaptive immunity
to prokaryotes, have revolutionized DNA targeting through the engineering of RNA-
programmable Cas9-based tools. Effective RNA-programmable RNA-targeting tools
would likewise transform RNA biology and biotechnology.
Class 2 CRISPR-Cas systems, which rely only on a single effector protein and
programmable CRISPR RNA (crRNA) to target nucleic acids, represent the most
promising tool to target RNA. Building on previous research, a biocomputational
pipeline was developed to discover novel functional class 2 CRISPR systems lacking
the canonical adaptive machinery of Cas1 and Cas2 at their genomic loci. Out of
this pipeline emerged the class 2 CRISPR-Cas RNA-targeting system, VI-B (Cas13b
with accessory Csx27/Csx28). Cas13b was characterized both biochemically and
genetically, and found to be differentially regulated—inhibited by Csx27 in VI-B1
systems and enhanced by Csx28 in VI-B2 systems. RNA-targeting rules are critical to
tool development, and so an E. coli essential gene screen was conducted and analyzed
to assess the RNA sequence and structure requirements for targeting. The completion
of this work advances both knowledge in the CRISPR field and possibilities in the
RNA-targeting toolkit.
Thesis Supervisor: Feng Zhang
Title: Associate Professor, Brain and Cognitive Sciences and Biological Engineering
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Chapter 1
Introduction
1.1 RNA Biology and Biotechnology
Ribonucleic acid (RNA) plays a dominant and dynamic role in human biology and
disease. According to the ‘central dogma’ of biology, deoxyribonucleic acid (DNA)
encodes for messenger RNA (mRNA) during transcription, which in turn encodes for
proteins during translation. DNA also encodes for noncoding RNA (ncRNA), which
can interact with DNA, proteins, and other RNA species (Figure 1-1). In the context
of ncRNA, this interaction may lead to chromatin modification, RNA polymerase
activity regulation, transcriptional interference, RNA spicing, RNA editing, mRNA
stability, and translation initiation (Wahlestedt, 2013). Additionally, ncRNA can take
on many forms, from ubiquitous ‘ribosomal RNA’ (rRNA), to translation adaptor
‘transfer RNA’ (tRNA), to post-transcriptional regulatory ‘microRNA’ (miRNA), to
‘long non-coding RNA’ (lncRNA) and other species.
Unlike DNA, of which there are two copies localized in the nucleus of diploid
cells (with the exception of mitochondrial DNA), an identical RNA molecule may be
present hundreds of times in a cell. Moreover, due to the relatively small size and
instability of RNA, intracellular diffusion and degradation can cause its concentra-
tion and spatial distribution to vary significantly over time. RNA is also actively
transported throughout cells by RNA binding proteins (RBPs), which may even load
RNA into extracellular vesicles, either for waste management or potentially intercel-
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Figure 1-1: ‘Central dogma’ in the context of regulatory non-coding RNAs.
Advances in transcriptomics have resulted in the discovery of large numbers of non-
coding RNAs (ncRNAs), many of which have the capacity to regulate gene expression
at transcriptional or translational levels. The concept of the ‘central dogma’, which
is complemented in this figure with aspects of ncRNA functions, was arguably first
formulated by Francis Crick in 1958: “Once information has passed into protein, it
cannot get out again. In more detail, the transfer of information from nucleic acid to
nucleic acid, or from nucleic acid to protein may be possible, but transfer from protein
to protein, or from protein to nucleic acid is impossible.” lncRNA, long non-coding
RNA; miRNA, microRNA. Figure and figure legend are from Wahlestedt (2013).
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lular communication.
Notwithstanding technological considerations, the sheer diversity and versatil-
ity of the ‘transcriptome’ (sum total of RNA molecules expressed from an organism’s
genes) has challenged many attempts at consistent RNA manipulation. A number of
applications for RNA-targeting with engineered RBPs have been proposed (Figure 1-
2), including translation modulation, splicing modulation, localization detection and
modulation, stabilization, degradation, and binding disruption (Mackay et al., 2011).
While most readily adaptable to basic research, these applications may also be trans-
lated to human disease diagnostics (Gootenberg et al., 2017) and therapeutics (Cox
et al., 2017).
RNA targeting invites multiple opportunities in synthetic biology, an emerging
biological field motivated by the principles of electrical engineering and computer
science. Over the last decade, efforts in programming cells, principally in bacteria
and yeast, have resulted in the invention and exploitation of novel, synthetic RNA
components (Isaacs et al., 2006). These components are based in design on natural
ncRNA regulators, be they ‘antisense’ that repress translation upon binding, ‘riboreg-
ulator’ that repress or activate translation upon binding, ‘ribozyme’ that repress or
activate translation upon cleavage, ‘riboswitch’ that repress or activate translation
upon ligand binding, or ‘structural scaffolds’ that connect other RNA components.
By combining customized synthetic RNA components in engineered biological
devices, researchers have realized applications in genetic circuitry, metabolic engineer-
ing, and biosensing (Chappell et al., 2015). Inspired by the diverse regulatory nature
of ncRNA, completely novel RNA aptamers, or short sequences that bind specifically
to target molecules through their 3-dimensional structures, have even been designed.
With the advent of next-generation sequencing, researchers can now computationally
create tens of thousands of rationally designed modular RNA aptamers and screen
them against a biological or chemical input to select for optimal affinity and specificity
(McKeague et al., 2016).
In the last few years, RNA synthetic biology has been translated to mammalian
biology. Following viral transduction of RNA components in human cells, researchers
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have implemented sophisticated logical and computational functions, such as multi-
input classification or regulation of transgene expression (Wroblewska et al., 2015).
These genetically precise approaches are at the frontier of treating complex diseases,
and offer multiple advantages over similar DNA-targeting techniques. First, they
do not require nuclear localization, often challenging in systemic delivery. Second,
they circumvent direct engineering of the genome, which may have off-target effects.
Finally, any RNA synthetic biology will be transient, and thus there is minimal risk
for persistent cellular perturbation. More effective RNA-targeting tools would expand
the advantages of RNA synthetic biology.
Until recently, only a few RNA-targeting applications had been realized. The
earliest such work can be traced back to the end of the previous century, when two
independent studies with the coat protein of the RNA bacteriophage MS2 led to suc-
cessful localization detection and stabilization of mRNA in eukaryotic cells (Bertrand
et al., 1998; Coller et al., 1998). Next, the discovery of RNA interference (RNAi) in
C. elegans would be exploited in mammalian cells (Elbashir et al., 2001). Both ap-
proaches would set the gold standard for in vivo RNA targeting for over a decade, yet
both would be severely limited–MS2 coat protein because it relies on either targeting
of exogenous RNA or inefficient autonomous hybridization with endogenous RNA,
and RNAi because it is an endogenous process whose associated proteins cannot be
modified.
14
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Figure 1-2: Possible uses of engineered RNA-binding proteins (RBPs). (a)
Fusing the eukaryotic translation initiation factor eIF4G to an RBP targeted to the 5′
untranslated repeat (5′ UTR) of a messenger-RNA (mRNA) could drive translation.
(b) An RBP that binds near the translational start codon could inhibit translation
of an mRNA. (c) A 5′ splice site-binding RBP could block recruitment of the U1
component of the spliceosome, favoring the skipping of that exon. (d) Conversely,
an RBP that recognizes a splicing enhancer site and is fused to an arginine- and
serine-rich (RS) domain could favor inclusion of the associated exon. (e) An RBP
fused to a fluorescent protein (such as GFP) could be used to track RNA localization
in living cells. (f) An RBP fused to a nuclear localization signal (NLS) could be
used to alter RNA localization. (g) An RBP fused to a protein such as Argonaute 2
(Ago2) and targeted to the 3′ UTR of an mRNA could promote the degradation of
the message. (h) Fusion of an RBP to a nonspecific RNase could allow the cutting of
a specific target RNA. This approach would work best using a split-RNase strategy
analogous to that used for the successful zinc-finger nucleases, preventing widespread
cleavage throughout the cell. (i) An RBP that tightly bound a specific noncoding
RNA (ncRNA) could block its activity, providing a useful functional probe. Figure
and figure legend are from Mackay et al. (2011).
In 2016, two unique studies shifted the paradigm in RNA targeting. In one pa-
per, the RNA-binding protein PumHD (Pumilio homology domain) was engineered
into a set of four canonical protein modules, each targeting a single RNA base (gua-
nine, cytosine, adenosine, or uracil), in a process called Pumilio-based assembly, or
‘Pumby’ (Adamala et al., 2016). Such assembly would mirror the previous con-
struction of the four canonical TALE protein modules targeting single DNA bases
(Miller et al., 2011). Due to the required protein engineering for each unique target
site, however, the use of Pumby in research can be costly in both time and material
resources. In the other 2016 paper, the RNA-programmable (as opposed to protein-
programmable) nuclease CRISPR-Cas9 that had revolutionized DNA-targeting was
co-opted to target RNA, and dubbed ‘RCas9’ (Nelles et al., 2016). As Cas9 is intrinsi-
cally DNA-targeting, however, the efficiency of RCas9 remains to be determined. The
following year, an intrinsically RNA-targeting CRISPR associated protein, Cas13, was
engineered by the Zhang Lab to target and edit RNA (Abudayyeh et al., 2017; Cox
et al., 2017). Two systems with unique protein architectures, Cas13a/c and Cas13b,
were both exploited.
Certain CRISPR-Cas (clustered regularly interspaced short palindromic repeats
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and CRISPR-associated proteins; also referred to as just CRISPR) systems have
been known to target RNA for about a decade, when the Cmr complex (type III-
B/C) was first found to interfere with the RNA of invading bacteriophages (Hale et
al., 2009). Five years later, the Csm complex (type III-A/D), which was initially
believed to target DNA, was instead described as RNA-targeting (Staals et al., 2014;
Tamulaitis et al., 2014). The 2015 biocomputational discovery of C2c2/Cas13a (type
VI-A) with predicted RNase activity (Shmakov et al., 2015) inspired further work
to characterize RNA-targeting class 2 CRISPR systems. Following this, I set up a
computational pipeline to look for additional class 2 CRISPR systems, and recruited
Neena Pyzocha to join me and analyze the candidates generated by my computational
pipeline. From these candidates, Neena and I identified Cas13b (type VI-B) and
proceeded to characterize its function. Since both Cas13a and Cas13b have been
predicted to target RNA, the study of both proteins became ongoing synergistic
projects in the Zhang Lab, resulting in highly complementary studies (Abudayyeh et
al., 2016; Smargon et al., 2017).
1.2 The CRISPR Field
CRISPR research originated accidentally in 1987, when the alkaline phosphate
isozyme-converting gene iap was cloned (Ishino et al., 1987), and an intriguing bit
of computational biology did not go unreported. In perhaps the most understated
sentence in biology, the authors wrote, “An unusual structure was found in the 3′-
end flanking region of iap” (Figure 1-3A). This structure, known as a ‘direct repeat’,
would form the basis for the CRISPR acronym, and more importantly the basis for
CRISPR adaptive immunity.
CRISPR-Cas systems, present in most archaea and roughly half of bacteria, help
protect prokaryotes against the foreign nucleic acids of invading viruses (Makarova et
al., 2006; Barrangou et al., 2007; Barrangou, 2013; Marraffini, 2015; Mohanraju et al.,
2016). While a few CRISPR systems target RNA, most characterized systems target
DNA (Koonin et al., 2017). CRISPR immunity is adaptive, and takes place in three
17
AB
Figure 1-3: CRISPR origins and adaptive immunity mechanism. (A) Sem-
inal finding of CRISPR direct-repeat sequence at 3′–end flanking region of iap, from
Ishino et al. (1987). (B) CRISPR adaptive immunity mechanism, from the website
of The Doudna Lab at UC Berkeley.
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stages: 1) foreign DNA is acquired as a spacer between direct repeats in the CRISPR
locus, which is then transcribed into pre-crRNA (pre-CRISPR RNA); 2) pre-crRNA is
processed into mature crRNA and complexed with the Cas protein(s); 3) the CRISPR
Cas-crRNA complex targets either DNA or RNA protospacers (sequences with reverse
complementarity to spacers) of invading viruses (Figure 1-3B).
CRISPR-Cas systems are divided into two classes: the more prominent class
1 whose CRISPR-Cas complex contains multiple essential effector proteins, and the
less abundant but highly diverse class 2 which relies on a single effector in complex
with crRNA to target nucleic acids (Makarova et al., 2015; Koonin et al., 2017).
These classes are further subdivided into types, defined by the Cas proteins involved
in various functions, such as expression, interference, adaptation, and ancillary roles
(Figure 1-4A). In 2015, prior to the commencement of my thesis research, five types of
CRISPR systems had been described: types I, III, and IV in class 1 and types II and
V in class 2 (Makarova et al., 2015). By 2017, six types have been described (including
class 2 type VI), with twelve class 1 subtypes and seventeen class 2 subtypes (Koonin
et al., 2017). These diverse class 2 subtypes are shown in Figure 1-4B.
Due to their compact nature, Class 2 CRISPR-Cas systems have proved in-
strumental in genome engineering applications since their initial exploitation in 2013
(Cong et al., 2013; Mali et al., 2013). The expanding diversity of these systems in
succeeding years has generated a series of potential new tools to target DNA and
now RNA, rendering previously speculative biology and biotechnology an accessible
reality. When I began my thesis research in 2015, however, only the class 2 DNA-
targeting effectors Cas9 and Cpf1 were known to the world (Jinek et al, 2012; Zetsche
et al., 2015).
1.3 Thesis Problem and Statement
CRISPR-Cas systems rely on the machinery of Cas1 and Cas2, and particularly Cas1,
in the adaption phase of immunity (Marraffini, 2015). Prior to this thesis work, it
was widely believed in the field that putative systems lacking this adaptive machinery
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Figure 1-4: CRISPR classifications (c. 2015) and class 2 CRISPR clas-
sifications (c. 2017). (A) Classification of CRISPR systems by class, type and
protein modules and functions, from Makarova et al. (2015). (B) Classification of
Class 2 CRISPR systems, from Koonin et al. (2017).
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would not be functional. For this reason, computational sequence database mining
for CRISPR-Cas systems had been carried out using the cas1 gene as a seed. This
reasoned approach led to the discovery of Cas13a (Shamkov et al., 2015), which was
uncharacterized experimentally when my thesis research commenced (but, again, the
Cas13a and Cas13b initial studies would play contemporaneous synergistic roles in the
Zhang Lab). Based on the absence of Cas1 and Cas2 in the proposed class 1 type IV
system, my colleagues and I hypothesized that using the CRISPR array as the search
seed may provide a more comprehensive census of CRISPR systems. Furthermore, if
one of these systems were RNA-targeting, the research may lead to utilities beyond
the CRISPR field.
My thesis statement can be put succinctly:
The aim of this research was to discover and characterize novel functional class
2 CRISPR systems. If any such systems targeted RNA, this research would help
expand and improve the experimental toolkit to study RNA biology and advance RNA
biotechnology.
In the remainder of the thesis, I fulfill this statement, at first through compu-
tational biology and later through biochemistry and genetics together with research
colleagues in the Zhang Lab. The outcome of this thesis is the class 2 CRISPR RNA-
targeting system Cas13b, which offers many opportunities for future research in RNA
biology and biotechnology.
1.4 Thesis Organization
This thesis is divided into four chapters and two appendices. In Chapter 1, this
introductory chapter, I provide background and motivation on RNA targeting and
the CRISPR field, as well as present my thesis problem and statement. In Chapter
2, I elaborate on the search for novel function class 2 CRISPR systems, culminating
in the discovery of Cas13b (type VI-B). Chapter 3 describes the characterization
of Cas13b as a differentially regulated RNA-targeting system represented by two
subtypes. In Chapter 4, I conclude with a summary and impact of my thesis, in
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addition to a discussion of future research directions. Appendix A contains the tables
relevant to Chapters 2 and 3. Appendix B comprises text from a 2017 Nature Reviews
Microbiology analysis article of Class 2 CRISPR system diversity and evolution on
which I am second author. Chapters 2 and 3 and Appendix B contain the work of
multiple individuals. At the beginning of each, I provide a full citation and state
my personal contributions. Altogether, these chapters and appendices encompass
research spanning computational biology, biochemistry, and genetics–an exemplar of
the interdisciplinary environment of today’s research in the life sciences.
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Chapter 2
Biocomputational Discovery of and
Initial Results with Cas13b
This chapter is derived in part from the Cas13b study published in Molecular Cell
(Smargon et al., 2017) and my Master’s Thesis (Smargon, 2016). Full citation is as
follows:
Smargon, A.A.*, Cox, D.B.T.*, Pyzocha, N.K.*, Zheng, K., Slaymaker, I.M.,
Gootenberg, J.S., Abudayyeh, O.A., Essletzbichler, P., Shmakov, S., Makarova, K.S.,
Koonin, E.V. and Zhang, F. (2017). Cas13b Is a Type VI-B CRISPR-Associated
RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28.
Mol. Cell 65, 618−630.e7. (* denotes co-first authors)
Computational Contributions: With feedback from F.Z., I designed and
implemented the biocomputational pipeline to discover new Class 2 CRISPR systems.
K.Z. and N.K.P. assisted with a few individual components of its implementation, and
N.K.P. assisted with curating the output of the pipeline. I performed the subsequent
computational sequence analysis of Cas13b and Type VI-B CRISPR systems, with
S.S., K.S.M., and E.V.K. providing input on annotation, classification, and naming.
Biochemical Contributions: Early on in the project, N.P., F.Z., and I work-
ing together optimized the nucleic acid preparation and nuclease assay, and designed
and implemented experiments. This included carrying out the first successful sin-
gle spacer BzCas13b RNA cleavage experiment and following up with spacer tiling
experiments.
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2.1 Summary
CRISPR-Cas adaptive immune systems defend microbes against foreign nucleic acids
via RNA-guided endonucleases. Using a computational sequence database mining
approach, here we identify two class 2 CRISPR-Cas systems (subtype VI-B) that
lack Cas1 and Cas2 and encompass a single large effector protein, Cas13b, along
with one of two previously uncharacterized associated proteins, Csx27 and Csx28.
We show that Cas13b processes its own CRISPR array with short and long direct
repeats, indicating that it may encapsulate a functional CRISPR system.
2.2 Introduction
CRISPR-Cas (clustered regularly interspaced short palindromic repeats and CRISPR-
associated proteins) systems are divided into two classes, class 1 systems, which utilize
multiple Cas proteins and CRISPR RNA (crRNA) to form an effector complex, and
the more compact class 2 systems, which employ a large, single effector with crRNA
to mediate interference (Makarova et al., 2015). CRISPR-Cas systems display a wide
evolutionary diversity, involving distinct protein complexes and different modes of
operation, including the ability to target RNA (Abudayyeh et al., 2016; East-Seletsky
et al., 2016; Hale et al., 2009; Jiang et al., 2016; Staals et al., 2013, 2014; Tamulaitis
et al., 2014).
Computational sequence database mining for diverse CRISPR-Cas systems has
been carried out by searching microbial genomic sequences for loci harboring the cas1
gene, the most highly conserved cas gene involved in the adaptation phase of CRISPR
immunity (Marraffini, 2015). Among other findings, this approach led to the discovery
of the class 2 subtype VI-A system with its signature effector Cas13a (previously
known as C2c2), which targets RNA (Abudayyeh et al., 2016; East-Seletsky et al.,
2016; Shmakov et al., 2015). Since distinct variants of class 1 CRISPR systems have
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been discovered that lack cas1 (Makarova et al., 2015), we sought to identify class 2
CRISPR-Cas systems lacking cas1 by modifying the computational discovery pipeline
so that it is not seeded on Cas1.
2.3 Computational Search for Novel Class 2
CRISPR Systems
We designed a computational pipeline to search specifically for putative class 2
CRISPR-Cas loci lacking Cas1 and Cas2. The pipeline consisted of two phases, a
CRISPR locus discovery phase (stages 1-3) and a class 2 candidate discovery phase
(stages 4-6) (Figure 2-1).
In the first phase of the pipeline, we annotated CRISPR loci from assembled mi-
crobial genomes. We downloaded ∼23K annotated assembled bacterial and archaeal
genomes from the Ensembl Release 27 (June 2015) (Yates et al., 2016). For refer-
ence, Ensembl Release 37 (December 2017) contains ∼44K such genomes, effectively
representing a doubling in just 2.5 years. Next, we searched for all CRISPR arrays
in these assembled genomes. To achieve this, we implemented PILER-CR, open-
source software for unbiased CRISPR array discovery that can scan through a “5Mb
genome in around 5 seconds on a [2007] desktop computer” (Edgar, 2007). We used
the default parameters, namely a minimum of 3 direct repeats with 90% sequence
conservation, repeats of size 16–64 nucleotides, and spacers of size 8–64 nucleotides.
With respect to previous CRISPR literature, PILER-CR with default parameters has
100% sensitivity and 94% specificity (Edgar, 2007).
From PILER-CR, we detected ∼25K CRISPR arrays in the ∼23K genomes.
Fewer than half of the genomes contained CRISPR arrays, and often a single genome
would contain three or more arrays, each with potentially distinct direct repeats. For
each of these arrays, we determined CRISPR loci by including all annotated genes
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Figure 1
5. Expand & cluster class 2 candidates
1. Compile annotated assembled genomes
2. Discover CRISPR arrays in genomes
3. Discover CRISPR loci in genomes
4. Filter loci for class 2 candidates
6. Manually curate & classify candidate loci
VI-B1  (Cas13b & Csx27)
VI-B2  (Cas13b & Csx28)
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Figure 2-1: Bioinformatic pipeline to discover putative class 2 CRISPR
loci lacking Cas1 and Cas2. Phase I is the CRISPR locus discovery phase, and
Phase II is the class 2 candidate discovery phase.
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10kb upstream and downstream of the detected arrays. Of the ∼25K defined CRISPR
loci, ∼13K did not possess Cas1 or Cas2 at the locus, and ∼12K contained a single
large effector, defined as only one protein greater than 700 amino acid (aa) residues
in length, and thus less likely to be part of a class 1 CRISPR system.
In the second phase of the pipeline, we examined the CRISPR loci for the
putative class 2 candidates most likely to be functional. The intersection of loci with
no Cas1 or Cas2 and with a single large effector reduced to ∼5K loci, or about 20%
of original CRISPR loci. These loci were further filtered to those most likely to be
functional and compact. Informed in part by the size of previously classified class 2
effectors, we chose a lower bound for putative single effector size of 900 aa. Due to
considerations of packaging in adeno-associated virus for systemic gene delivery, we
chose an upper bound of 1800 aa. This further reduced the list of putative class 2
CRISPR systems to ∼1500 candidates.
To find all homologous proteins to these candidates for later analysis, we per-
formed NCBI BLAST on the ∼1500 candidate single effectors against the NCBI
non-redundant protein database (Camacho et al., 2009). Through an exhaustive ho-
mology search with an E-value cutoff of 1e-7, the list of class 2 candidates grew to
∼7200. From here, we clustered candidate loci through a nearest-neighbor E-value
cutoff of 1e-7, which yielded 266 groups. After generating visualization outputs for
each unique locus, we manually inspected these 266 groups containing ∼7200 loci.
For the most accurate classification, this inspection occurred one locus at a time per
group. Interestingly, often a CRISPR system would span multiple groups, or one
group might contain multiple CRISPR systems—highlighting the imperfection of au-
tomated pipelines and confirming the necessity of manual curation one locus at a
time.
Each locus was analyzed first for architecture, namely the position and orienta-
tion of CRISPR-Cas and other annotated proteins near the CRISPR array (Figure 2-
27
amino acids
0 200 400 600 800 1000 1200
Crispr-associated endonuclease CAS9/CSN1
100%
HNH endonuclease domain protein
100%
HNH endonuclease
96.9%
Restriction endonuclease PACI
95.6%
Hypothetical protein
79.1%
Putative holliday junction resolvase
79.1%
Holliday junction resolvase (RUVC)
78.8%
Hypothetical protein YQGF
78.5%
Ethanolamine utilization protein EUTJ
75.3%
Crossover junction endodeoxyribonuclease RUVC
74.1%
WP_002841804.1 (1348 aa):
CRISPR-associated protein Cas9 [Finegoldia magna]
base pairs x 104
-1.5 -1 -0.5 0 0.5 1 1.5
-16
>
-15
>
-14
>
-13
<
-12
<
-11
<
-10
<
-9
<
-8
>
-7
>
-6
>
-5
>
-4
<
-3
<
-2
<
-1
<
0
<
1
>
2
<
3
<
4
<
5
<
6
<
7
<
8
<
9
<
10
<
NZ_AFUI01000017.1 (69681 bp [7341-37341]):
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Figure 2-2: Representative pipeline visualization output for Finegoldia
magna Cas9: candidate locus plot and protein homology. (A) Genome ac-
cession number, length, range, and name above graph of genomic locus containing
CRISPR array in red and proteins in blue (selected protein), magenta (annotated
Cas1, Cas 2), orange (other annotated CRISPR associated proteins), and white (all
other proteins) with protein orientations depicted. (B) Select protein accession num-
ber, length, and name above top 10 HHpred homology hits and their respective prob-
abilities.
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2A). To check if the putative class 2 effector contained known catalytic domains, we
performed HHpred, a hidden Markov homology model that predicts the likelihood of
a protein containing established protein domains and subdomains (Hildebrand et al.,
2009; Remmert et al., 2011). The top 10 protein domain and subdomain predictions
were then plotted along the protein to aid in visualization (Figure 2-2B).
After inspecting the locus architecture and predicted single effector do-
mains/subdomains, we were next interested in whether we could classify, and thus
exclude, a candidate system as an existing CRISPR system. Here it was useful to
examine the genes nearby the single effector for annotated CRISPR-Cas proteins (Fig-
ure 2-3A), and also to study the consensus direct repeat as determined by PILER-CR
(Figure 2-3B). Together, we synthesized this information into a CRISPR system clas-
sification decision tree based on prior CRISPR-Cas system classification literature
Figure 2-3C) (Makarova et al., 2015).
Having examined each locus in each group, we designated the 266 groups as
containing one or more systems, either characterized CRISPR, characterized non-
CRISPR, or uncharacterized. A number of characterized class 2 CRISPR systems
containing Cas1 and Cas2 (e.g., Cas9, Cpf1, and Cas13a) slipped through the search,
likely because one or more homologs of an effector lost both Cas1 and Cas2 at its
locus during evolution. Outside of known class 2 CRISPR systems, we filtered out
several categories of proteins from consideration. Most numerous were those well cat-
egorized by HHpred (greater than 80% homology to known non-CRISPR proteins)
and of which only one or two group members were proximal to a CRISPR array.
These included helicases, ATPases, kinases, proteases, and transferases, among other
proteins. Second most numerous were those groups containing only one or two pro-
teins. Third most numerous were class 1 CRISPR loci that had passed the large
single effector filter, mainly Cas3 but occasionally Csm and Cmr proteins.
In the end, we were interested in uncharacterized single effectors most likely
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Figure 2-3: Representative pipeline visualization output for Finegoldia
magna Cas9: candidate locus genes, CRISPR arrays, and tentative
CRISPR classifications. (A) Key of genes nearby select proteins with index,
accession number, length in amino acids, and name. (B) CRISPR arrays in genome
with distance from select protein (negative if upstream of protein), number of repeats,
length of repeats, length of spacers, and consensus repeat sequence. (C) Tentative
CRISPR classifications from decision tree based on existing literature.
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to encompass class 2 CRISPR systems. Thus, we considered only groups or merged
groups of which we could be most confident—namely those with greater than 10
distinct candidates, greater than 50% of which contained CIRSPR arrays at their
loci. This ruled out a number of candidates that had piqued our curiosity, including
proteins annotated as methylases, transposases, integrases, and nucleases. Based on
all the aforementioned considerations, we settled exclusively on the merged Groups
29 and 30.
2.4 Discovery of Class 2 Subtype VI-B System with
Cas13b
Groups 29 and 30 held a protein (‘hypothethical protein’) with no confident do-
main/subdomain predictions by HHpred (Figure 2-4A) and only a similarity to type
II and IV systems by its 36 nucleotide CRISPR direct repeat (Figure 2-4B). No known
CRISPR-Cas proteins were present at any of loci in immediate proximity (Figure 2-
4C), indicating that this putative system was isolated in all respects except by its
CRISPR array. This led us to search for any nearby proteins that might be conserved
in relative position and orientation to the candidate effector. By iterating on this
approach, we discovered two additional proteins, ‘small protein 1’ and ‘small protein
2’. (After experiments described in Chapter 3, these small proteins would eventually
become ‘Csx27/Csx28’, while the candidate effector became ‘Cas13b’.)
Groups 29 and 30 formed two genetically diverse putative class 2 CRISPR-
Cas systems (105 genomic loci, 81 containing a unique entry Cas13b in the
non-redundant NCBI protein database, and 71 of these 81 containing an an-
notated CRISPR array) represented in Gram-negative bacteria (Figure 2-6A).
For some genera, in particular Porphyromonas and Prevotella, Cas13b pro-
teins are encoded in several unique sequenced loci and, occasionally, in the
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Figure 2-4: Critical elements of pipeline visualization output for manual
curation of Bergeyella zoohelcum Cas13b (originally “hypothetical protein”
in Group 29). (A) Select protein accession number, length, and name above top
10 HHpred homology hits and their respective probabilities. (B) CRISPR arrays in
genome with distance from select protein (negative if upstream of protein), number
of repeats, length of repeats, length of spacers, and consensus repeat sequence.
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same sequenced genome. These systems often co-occur with other CRISPR-
Cas systems. Of the 81 type VI-B loci found across complete and incom-
plete bacterial genomes, 62 also possess at least one other CRISPR-Cas locus
that includes the key adaptation endonuclease, Cas1. However, three complete
genomes carrying the type VI-B locus (Flavobacterium_branchiophilum_FL_15
_GCA_000253275.1, Paludibacter_propionicigenes_WB4_GCA_000183135.1, and
Porphyromonas_gingivalis _AJW4_GCA_001274615.1) lack Cas1 altogether (Fig-
ure 2-6A).
All VI-B loci encode a large (∼1,100 aa) candidate effector protein and, in about
80% of the cases, an additional small (∼200 aa) protein (Figures 2-5 and 2-6A). The
putative effector proteins contain two predicted HEPN domains (Anantharaman et
al., 2013) at their N and C termini (Figure 2-6B), similar to the domain architecture
of the large effector of subtype VI-A (Cas13a) (Shmakov et al., 2015). Beyond the
occurrence of two HEPN domains, however, there is no significant sequence similarity
between the predicted effector and Cas13a. These systems were also identified by a
generalized version of the pipeline described above as part of a comprehensive analysis
of class 2 CRISPR-Cas systems and were classified into subtype VI-B, with predicted
effector protein Cas13b (Shmakov et al., 2017).
33
Figure 1
Bergeyella zoohelcum ATCC 43767
Psychroflexus torquis ATCC 700755
Porphyromonas gingivalis ATCC 33277
Bacteroides pyogenes JCM 10003
Alistipes sp. Z0R0009
Phaeodactylibacter xiamenensis
Prevotella sp. P5-125
Capnocytophaga canimorsus Cc5
Flavobacterium branchiophilum FL-15
Prevotella sp. MA2016
Flavobacterium columnare ATCC 49512
Riemerella anatipestifer ATCC 11845
Prevotella saccharolytica JCM 17484
Prevotella buccae ATCC 33574
Porphyromonas gulae
Su
by
pe
 V
I-B
1
Su
bt
yp
e 
VI
-B
2
SpacerDR
(11)
(51)
(19)
(12)
(18)
(7)
(19)
(7)
(9)
(16)
(7)
(12)
(5)
(16)
(20)
Cas13b Csx27 Csx28
Figure 2-5: Discovery of Two Class 2 CRISPR-Cas Systems, Subtype VI-
B1 and VI-B2, Containing Cas13b. A schematic phylogenetic tree of the subtype
VI-B loci. Loci with Csx27 (brown) comprise variant VI-B1; loci with Csx28 (gold)
comprise variant VI-B2. Strains in blue (Bergeyella zoohelcum ATCC 43767 and
Prevotella buccae ATCC 33574 ) were characterized experimentally. See also Fig-
ures 2-6, 2-7, and 3-10.
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Figure S1
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Species (Genome Accession) Cas13b Accession Csx27/28 Accession # Spacers Cas1 in genome? Cas13b Size (aa)
Paludibacter propionicigenes WB4 (NC_014734.1) WP_013446107.1 NA 8 N 1155
Prevotella sp. P5-60 (NZ_JXQJ01000080.1) WP_044074780.1 NA 5 Y 1091
Prevotella sp. P4-76 (NZ_JXQI01000021.1) WP_044072147.1 NA 0 ? 1091
Prevotella sp. P5-125 (NZ_JXQL01000055.1) WP_044065294.1 NA 11 ? 1091
Prevotella sp. P5-119 (NZ_JXQK01000043.1) WP_042518169.1 NA 11 Y 1091
Capnocytophaga canimorsus Cc5 (NC_015846.1) WP_013997271.1 WP_013997274.1 51 Y 1200
Phaeodactylibacter xiamenensis (NZ_JPOS01000018.1) WP_044218239.1 WP_044218241.1 19 Y 1132
Porphyromonas gingivalis W83 (NC_002950.2) WP_005873511.1 WP_005873518.1 7 Y 1136
Porphyromonas gingivalis F0570 (NZ_KI259168.1) WP_021665475.1 WP_021665476.1 3 Y 1136
Porphyromonas gingivalis ATCC 33277 (NC_010729.1) WP_012458151.1 WP_012458152.1 12 Y 1136
Porphyromonas gingivalis F0185 (AWVC01000122.1) ERJ81987.1 ERJ81988.1 0 Y 1136
Porphyromonas gingivalis F0185 (NZ_KI259960.1) WP_021677657.1 WP_021677658.1 6 Y 1136
Porphyromonas gingivalis SJD2 (NZ_KI629875.1) WP_023846767.1 WP_005873518.1 4 Y 1136
Porphyromonas gingivalis F0568 (AWUU01000145.1) ERJ65637.1 ERJ65638.1 3 Y 1136
Porphyromonas gingivalis W4087 (AWVE01000130.1) ERJ87335.1 ERJ87336.1 2 Y 1136
Porphyromonas gingivalis W4087 (NZ_KI260263.1) WP_021680012.1 WP_005873518.1 4 Y 1136
Porphyromonas gingivalis F0568 (NZ_KI258981.1) WP_021663197.1 WP_021663198.1 6 Y 1136
Porphyromonas gingivalis (NZ_LOEL01000010.1) WP_061156637.1 WP_005873518.1 11 Y 1136
Porphyromonas gulae (NZ_JRAQ01000019.1) WP_039445055.1 WP_039445052.1 10 Y 1136
Bacteroides pyogenes F0041 (KE993153.1) ERI81700.1 ERI81699.1 5 Y 1116
Bacteroides pyogenes JCM 10003 (NZ_BAIU01000001.1) WP_034542281.1 WP_034542279.1 18 Y 1116
Alistipes sp. ZOR0009 (NZ_JTLD01000029.1) WP_047447901.1 NA 7 ? 954
Flavobacterium branchiophilum FL-15 (NC_016001.1) WP_014084666.1 WP_014084665.1 19 N 1151
Prevotella sp. MA2016 (NZ_JHUW01000010.1) WP_036929175.1 NA 7 ? 1323
Myroides odoratimimus CCUG 10230 (AGEC02000017.1) EHO06562.1 EHO06560.1 2 Y 1160
Myroides odoratimimus CCUG 3837 (AGZK01000016.1) EKB06014.1 EKB06015.1 0 ? 1158
Myroides odoratimimus CCUG 3837 (NZ_JH815535.1) WP_006265509.1 WP_006265510.1 0 ? 1158
Myroides odoratimimus CCUG 12901 (NZ_JH590834.1) WP_006261414.1 WP_006261415.1 0 ? 1158
Myroides odoratimimus CCUG 12901 (AGED01000033.1) EHO08761.1 EHO08762.1 0 ? 1158
Myroides odoratimimus (NZ_CP013690.1) WP_058700060.1 WP_006261415.1 10 Y 1160
Bergeyella zoohelcum ATCC 43767 (AGYA01000037.1) EKB54193.1 EKB54194.1 9 Y 1225
Capnocytophaga cynodegmi (NZ_CDOD01000002.1) WP_041989581.1 WP_041989578.1 7 ? 1219
Bergeyella zoohelcum ATCC 43767 (NZ_JH932293.1) WP_002664492.1 WP_034985946.1 8 Y 1225
Flavobacterium sp. 316 (NZ_JYGZ01000003.1) WP_045968377.1 NA 0 Y 1156
Psychroflexus torquis ATCC 700755 (NC_018721.1) WP_015024765.1 NA 16 Y 1146
Flavobacterium columnare ATCC 49512 (NC_016510.2) WP_014165541.1 NA 7 Y 1180
Flavobacterium columnare (NZ_CP013992.1) WP_060381855.1 NA 5 Y 1214
Flavobacterium columnare (NZ_CP015107.1) WP_063744070.1 NA 3 Y 1214
Flavobacterium columnare (NZ_CP016277.1) WP_065213424.1 NA 14 Y 1215
Chryseobacterium sp. YR477 (NZ_KN549099.1) WP_047431796.1 NA 0 ? 1146
Riemerella anatipestifer ATCC 11845 = DSM 15868 (NC_014738.1) WP_004919755.1 WP_004919758.1 12 Y 1096
Riemerella anatipestifer RA-CH-2 (NC_020125.1) WP_015345620.1 WP_004919758.1 12 Y 949
Riemerella anatipestifer (NZ_CP007504.1) WP_049354263.1 WP_004919758.1 11 Y 949
Riemerella anatipestifer (NZ_LUDU01000012.1) WP_061710138.1 WP_061710139.1 13 Y 951
Riemerella anatipestifer (NZ_LUDI01000010.1) WP_064970887.1 WP_064970885.1 4 Y 1096
Prevotella saccharolytica F0055 (AMEP01000091.1) EKY00089.1 EKY00090.1 0 ? 1151
Prevotella saccharolytica JCM 17484 (NZ_BAKN01000001.1) WP_051522484.1 NA 5 Y 1152
Prevotella buccae ATCC 33574 (AEPD01000005.1) EFU31981.1 EFU31982.1 16 Y 1128
Prevotella buccae ATCC 33574 (NZ_GL586311.1) WP_004343973.1 WP_004343974.1 16 Y 1128
Prevotella buccae D17 (NZ_GG739967.1) WP_004343581.1 WP_004343582.1 8 ? 1128
Prevotella sp. MSX73 (NZ_ALJQ01000043.1) WP_007412163.1 WP_036927782.1 13 Y 1128
Prevotella pallens ATCC 700821 (AFPY01000052.1) EGQ18444.1 EGQ18443.1 4 ? 1126
Prevotella pallens ATCC 700821 (NZ_GL982513.1) WP_006044833.1 WP_050795200.1 4 ? 1126
Prevotella intermedia ATCC 25611 = DSM 20706 (NZ_JAEZ01000017.1) WP_036860899.1 WP_050795200.1 11 Y 1127
Prevotella intermedia (NZ_LBGT01000010.1) WP_061868553.1 NA 27 Y 1121
Prevotella intermedia 17 (CP003502.1) AFJ07523.1 AFJ07898.1 16 Y 1135
Prevotella intermedia (NZ_AP014926.1) WP_050955369.1 WP_014708440.1 16 Y 1133
Prevotella intermedia (AP014598.1) BAU18623.1 BAU18624.1 6 Y 1134
Prevotella intermedia ZT (ATMK01000017.1) KJJ86756.1 KJJ86755.1 2 ? 1126
Prevotella aurantiaca JCM 15754 (NZ_BAKF01000019.1) WP_025000926.1 WP_036889078.1 5 Y 1125
Prevotella pleuritidis F0068 (NZ_AWET01000045.1) WP_021584635.1 WP_021584705.1 6 Y 1140
Prevotella pleuritidis JCM 14110 (NZ_BAJN01000005.1) WP_036931485.1 WP_024991772.1 7 Y 1117
Prevotella falsenii DSM 22864 = JCM 15124 (NZ_BAJY01000004.1) WP_036884929.1 WP_051527348.1 10 Y 1134
Porphyromonas gulae (NZ_JRAT01000012.1) WP_039418912.1 WP_052073447.1 11 Y 1176
Porphyromonas sp. COT-052 OH4946 (NZ_JQZY01000014.1) WP_039428968.1 WP_050563578.1 12 Y 1176
Porphyromonas gulae (NZ_JRFD01000046.1) WP_039442171.1 WP_050563578.1 9 Y 1175
Porphyromonas gulae (NZ_JRAJ01000010.1) WP_039431778.1 WP_046201041.1 2 Y 1176
Porphyromonas gulae (NZ_KQ040500.1) WP_046201018.1 WP_046201041.1 4 Y 1176
Porphyromonas gulae (NZ_JRAL01000022.1) WP_039434803.1 WP_039434800.1 20 Y 1176
Porphyromonas gulae (NZ_JRAI01000002.1) WP_039419792.1 WP_052078041.1 9 Y 1120
Porphyromonas gulae (NZ_JRAK01000129.1) WP_039426176.1 WP_039426172.1 6 Y 1120
Porphyromonas gulae (NZ_KN294104.1) WP_039437199.1 WP_052102013.1 0 Y 1120
Porphyromonas gingivalis TDC60 (NC_015571.1) WP_013816155.1 WP_043890185.1 2 Y 1120
Porphyromonas gingivalis ATCC 33277 (NC_010729.1) WP_012458414.1 WP_012458413.1 4 Y 1120
Porphyromonas gingivalis A7A1-28 (NZ_CP013131.1) WP_058019250.1 WP_043898408.1 6 Y 1176
Porphyromonas gingivalis JCVI SC001 (APMB01000175.1) EOA10535.1 EOA10563.1 5 ? 1176
Porphyromonas gingivalis W50 (NZ_AJZS01000051.1) WP_005874195.1 WP_010955981.1 2 Y 1176
Porphyromonas gingivalis (NZ_CP011995.1) WP_052912312.1 WP_010955981.1 7 Y 1176
Porphyromonas gingivalis AJW4 (NZ_CP011996.1) WP_053444417.1 WP_043898408.1 11 N 1120
Porphyromonas gingivalis (NZ_CP007756.1) WP_039417390.1 WP_021665928.1 5 Y 1120
Porphyromonas gingivalis (NZ_LOEL01000001.1) WP_061156470.1 WP_021663076.1 5 Y 1120
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Figure 2-6: Phylogenetic tree of Cas13b bifurcates into two variants of
subtype VI-B CRISPR loci. Related to Figure 2-5. (A) A phylogenetic
tree (alignment generated by BLOSUM62) of non-redundant Cas13b effectors, with
the full type VI-B locus depicted in every instance. Accession numbers for genome,
Cas13b (blue), and Csx27 (brown)/Csx28 (gold) are included, as well as number of
nearby spacers detected by PILER-CR, the presence of Cas1 in the sequenced genome,
and the size of Cas13b. (B) Two HEPN sequences identified via multiple sequence
alignment (BLOSUM62) of putative non-redundant Cas13b proteins. (C) Divergent
HEPN sequence identified via multiple sequence alignment (BLOSUM62) of putative
non-redundant Csx28 proteins.
2.5 CRISPR-Cas13b Loci Contain Small Accessory
Proteins
The identity of the putative accessory protein correlates with the two distinct branches
in the phylogenetic tree of Cas13b (Figures 2-5 and 2-6A) (Henikoff and Henikoff,
1992), indicative of the existence of two variant systems, which we denote VI-B1
(accessory protein referred to as Csx27) and VI-B2 (accessory protein referred to
as Csx28). While subtype VI-B2 systems almost invariably contain csx28, csx27
is less consistently represented in VI-B1 loci. The protein sequences of Csx27 and
Csx28 show no significant similarity to any previously identified Cas proteins. (These
proteins are characterized in Chapter 3.)
2.6 Cas13b-Associated CRISPR Arrays Display
Unique Features
In contrast to their differing putative accessory proteins, both variants of subtype
VI-B systems show distinct, conserved features in the CRISPR arrays. The direct
repeats in the CRISPR arrays are conserved in size, sequence, and structure, with
a length of 36 nt, a poly-U stretch in the open loop region, and complementary
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sequences 5′-GUUG and CAAC-3′ at the ends of the repeat predicted to yield a defined
secondary structure mediated by intramolecular base-pairing (Figures 2-7A− 2-7C)
(Lorenz et al., 2011). Our analysis revealed 36 Cas13b spacers mapped with greater
than 80% homology to unique protospacers in phage genomes. Twenty-seven of the
identified Cas13b spacers targeted the coding strand of phage mRNA, while seven
spacers targeted the noncoding strand and two spacers targeted regions of the phage
genome without predicted transcripts. Although the composite of these imperfect
mappings revealed no consensus flanking region sequence (Figure 2-7D) (Biswas et
al., 2013), the well-conserved protospacer length of 30 nt, combined with the conserved
direct repeat sequence and length, suggests that the nucleic acid targeting rules may
be similar among different VI-B loci.
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Figure 2-7: Predicted sequence and secondary structure of type VI-B di-
rect repeats; predicted protospacer flanking sequences. Related to Fig-
ure 2-5. (A) Predicted secondary structure folds of structurally unique CRISPR
class 2 type VI-B1 direct repeats (Vienna RNAfold). (B) Predicted secondary struc-
ture folds of structurally unique CRISPR Class 2 type VI-B2 direct repeats. (C)
Weblogo of all unique VI-B direct repeat sequences of length 36 nt, taken as the same
transcriptional orientation as Cas13b. (D) Weblogo of all unique VI-B protospacer
flanking sequences from CRISPRTarget mapping of protospacers to phage databases.
2.7 Cas13b Processes Its Associated CRISPR Array
With the VI-B system classified computationally, it was time to turn to experimental
validation. A critical proof-of-concept experiment for characterizing any CRISPR
system is testing for RNA processing of its associated CRISPR array, for, if processing
does not occur to produce mature crRNA from pre-crRNA, the system is unlikely to
be functional in subsequent programmable targeting of nucleic acids. To test CRISPR
array processing for putative class 2 CRISPR-Cas13b, we conducted complementary
experiments. Genetically, we performed RNA sequencing of native B. zoohelcum to
determine whether pre-crRNA processing occurs in vivo. Following up biochemically,
we performed an in vitro cleavage assay with purified Cas13b from B. zoohelcum and
synthesized pre-crRNA associated with the same system.
RNA sequencing of the total RNA from B. zoohelcum (subtype VI-B1) showed
processing of the pre-crRNA into a 66 nt mature crRNA, with the full 30 nt 5′ spacer
followed by the 3′ direct repeat (Figure 2-8A) (Heidrich et al., 2015; Li and Durbin,
2009; Shmakov et al., 2015). A longer 118 nt crRNA, distal to the 36 nt crRNAs in
the CRISPR array and with a direct repeat consisting of 5′ and 3′ fragments of the
36 nt direct repeat sequence interrupted by an intervening repeat sequence, was also
processed. This phenomenon was computationally predicted to occur in additional
VI-B loci, such as those from Capnocytophaga canimorsus, Myroides odoratimimus,
and Riemerella anatipestifer.
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Figure 2-8: Cas13b from the VI-B1 Locus Processes a CRISPR Array with
Two Direct Repeat Variants. (A) RNA sequencing of the native VI-B1 locus from
Bergeyella zoohelcum ATCC 43767. (B) Denaturing gel showing cleavage products
of in vitro-synthesized short-DR-containing or long-DR-containing CRISPR arrays
from the B. zoohelcum genome by either wild-type or HEPN mutant BzCas13b (D1,
R116A/H121A; D2, R1177A/H1182A; and Q, R116A/H121A/R1177A/H1182A).
The schematic shows fragment lengths of a cleaved CRISPR array. See also Fig-
ure 2-9 and Table S1.
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Figure 2-9: Protein gels of purified WT BzCas13b and three mutant Bz-
Cas13b proteins. Related to Figures 2-8, 3-4, and 3-8. Denaturing protein
gels of B. zoohelcum wildtype, D1 (R116A/H121A mutant), D2 (R1177A/H1182A)
mutant, and Q (R116A/H121A/R1177A/H1182A) mutant Cas13b.
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Other CRISPR class 2 effectors are known to process their arrays without in-
volvement of additional RNases (East-Seletsky et al., 2016; Zetsche et al., 2015). Sim-
ilarly, we find that purified BzCas13b is capable of cleaving its associated CRISPR
array, generating mature crRNAs with short or long direct repeats, and spacers which
are not further processed beyond 30 nt, an activity which is not affected by muta-
tion of the predicted catalytic residues of the HEPN domain (Figures 2-8B and 2-9;
Table S1 and Table S2). Both genetically and biochemically we experimentally vali-
dated a computational prediction of functional CRISPR systems, namely that Cas13b
processes its associated CRISPR array.
2.8 Discussion
The biocomputational pipeline described in this chapter led to the discovery of the
first putative class 2 CRISPR system lacking the canonical adaptive machinery of
Cas1 and Cas2. Given its success, this computational approach could be generalized
to discover other interesting–CRISPR or non-CRISPR–systems in genomes. A more
abstract algorithm might look something like this (with my specific implementation
in parentheses):
1. Collect genomes of species of interest (Ensembl Release 27 compiled prokaryotic
genomes);
2. For each genome, run a sub-algorithm (PILER-CR) to detect landmarks
(CRISPR arrays) of systems of interest (CRISPR-Cas systems);
3. For each landmark in each genome, reconstruct a locus from proximal (10kb
upstream and downstream of CRISPR arrays) annotated genes and transcripts
(genes only);
4. Filter all discovered loci for constraining features (putative class 2 CRISPR
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systems lacking Cas1 and Cas2) of interesting systems;
5. Expand loci by searching for all features homologous to constraining features
(NCBI BLAST of class 2 candidate effectors), then reconstructing any addi-
tional loci as in Steps 1-3;
6. Hierarchically cluster (nearest-neighbor NCBI BLAST E-value) loci by con-
straining features, and manually classify putative novel systems from visual
output (based on existing CRISPR classifications, and observing the presence
or absence of noteworthy conserved genes, transcripts, sequences, and domains
within the systems).
Such an algorithm could be applied to a host of biocomputational problems, for
instance discovering novel immune systems in prokaryotes, or searching for transpos-
able elements or endogenous retroviruses in eukaryotes, or tracking variable genomic,
epigenomic, and/or transcriptomic sequences in cancer, immunology, neuroscience,
or development. With the growing amount of data in biology, and with the im-
perfection of any purely artificial intelligence algorithms, such ‘landmark-proximal
feature-clustering’ approaches may be necessary for certain future projects in the
field. Indeed, this algorithm proved instrumental in identifying Cas13b.
After the initial biocomputational discovery, the in vivo and in vitro CRISPR
array processing assays were essential go-no go experiments to any subsequent genetic
and biochemical characterization of Cas13b. Putative CRISPR systems without the
ability to process their associated CRISPR arrays cannot form mature crRNAs in
complex, and thus cannot defend against invading bacteriophages. Had these experi-
ments been unsuccessful, we likely would have attempted the same with other Cas13b
orthologs. In this manner, we could have tested whether the CRISPR inactivity were
due to the evolutionary degeneration of a few orthologs or whether this inactivity
generalized to the entire VI-B system. If processing occurred in vivo but not in vitro,
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we would have performed the equivalent biochemical experiments either with other
purified CRISPR proteins (for example, Cas1, Cas2, and Csx27/Csx28) or bacterial
lysates of other CRISPR proteins, with the appropriate controls.
Thankfully these initial CRISPR array processing experiments were successful,
prompting us to investigate the nature of Cas13b functionality. At this point in the
research, many exciting questions remained. For instance, does Cas13b indeed target
RNA? Are both VI-B direct repeat variants functional? And what are the roles of
Csx27 and Csx28? These questions and more are answered in Chapter 3.
2.9 Methods
2.9.1 Experimental Model and Subject Details
E. coli E. coli was grown in LB at 37∘C at 250 rpm overnight.
One Shot Stbl3 E. coli E. coli was grown in LB at 37∘C at 250 rpm overnight.
B. zoohelcum B. zoohelcum ATCC 43767 was grown in ATCC medium 44 (Brain
Heart Infusion broth) at 37∘C at 250 rpm overnight.
One Shot BL21(DE3)pLysE Chemically Competent E. coli The BzCas13b
expression construct (Table S2) was transformed into One Shot BL21(DE3)pLysE
(Invitrogen) cells. 25 mL of 6hr growing culture were inoculated into 2 l of Terrific
Broth 4 growth media (12 g/L tryptone, 24 g/L yeast extract, 9.4 g/L K2HPO4,
2.2 g/L KH2PO4, Sigma). Cells were then grown at 37∘C to a cell density of 0.6
OD600, and then SUMO-BzCas13b expression was induced by supplementing with
IPTG to a final concentration of 500 mM. Induced culture was grown for 16-18 hr
before harvesting cell paste, which was stored at −80∘C until subsequent purification.
For each BzCas13b mutant, 1 L of Terrific Broth was used to generate cell paste and
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all other reagents were scaled down accordingly. Protein purification was performed
using the same protocol as wild-type Cas13b. PbCas13b was cloned into the same
pET based vector and purified using a similar protocol as BzCas13b with the following
differences: cells were grown at 21∘C for 18 hr.
2.9.2 Method Details
Computational Sequence Analysis From complete compiled Ensembl Release
27 genomes (Yates et al., 2016), CRISPR repeats were identified using PILER-CR
(Edgar, 2007). Proteins within 10kb of identified CRISPR arrays were clustered into
loci, with loci rejected if more than one protein of size 700 amino acids or larger or
if either Cas1 or Cas2 were present. For candidate Class 2 effectors, only proteins
in these remaining loci of size 900aa to 1800aa were selected. These candidate effec-
tors were subjected to the BLASTP (Camacho et al., 2009) search against the NCBI
non-redundant (NR) protein sequence database with an E-value cutoff of 1e-7. All
discovered proteins were then grouped into putative families via a nearest-neighbor
grouping with the same E-value cutoff. Only putative families with at least ten can-
didate effectors and more than 50% of candidate effectors within 10kb of CRISPR
arrays were considered. HHpred (Remmert et al., 2011) and existing CRISPR locus
classification rules (Makarova et al., 2015) were used to classify each family, leaving
Cas13b as the only unclassified family. Additional Cas13b proteins in the family
were found through a nearest-neighbor search of previously discovered Csx27/Csx28
against the NCBI non-redundant (NR) protein sequence database with an E-value
cutoff of 1e-7, and then by searching in genomes within 1kb of any newly discovered
Csx27/Csx28. Within this Cas13b family, truncated or suspected partially sequenced
effectors were discarded, leaving 105 loci, and 81 with a unique protein accession
number in the NCBI non-redundant (NR) protein sequence database. Multiple se-
quence alignments on these 81 proteins (as well as the accessory Csx27 and Csx28
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proteins) were performed using BLOSUM62 (Henikoff and Henikoff, 1992) to identify
the HEPN domains and to sort the loci into phylogenetic trees. Loci represented in
the tree of 81 non-redundant proteins were selected first for annotated Csx27/Csx28
within 1kb of Cas13b, and next for annotated CRISPR array within 10kb of Cas13b.
Vienna RNAfold (Lorenz et al., 2011) was used to predict the secondary structure
of each direct repeat, whose transcriptional orientation was chosen as identical to
that of Cas13b in its locus. CRISPRTarget (Biswas et al., 2013) was used to search
the spacers in each locus against NCBI phage and plasmid genomes. Weblogos were
generated for all unique direct repeats and protospacer flanking sequences (Crooks
et al., 2004). TMHMM Server v. 2.0 (Möller et al., 2001) was used to predict the
transmembrane helices in Csx27 and Csx28.
Bacterial RNA-Sequencing RNA was isolated and prepared for sequencing us-
ing a modification of a previously described protocol (Heidrich et al., 2015; Shmakov
et al., 2015). RNA was isolated from 5 mL of stationary phase of bacterial cultures
by resuspending pelleted cells in 1mL of TRIzol (ThermoFisher Scientific) and then
homogenizing with 300 uL zirconia/silica beads (BioSpec Products) in a BeadBeater
(BioSpec Products) for 7 1 min cycles. 200 uL of chloroform was added to the homog-
enized sample and then samples were centrifuged for 15 min. (12000xg, 4∘C). The
aqueous phase was then used for input into the Direct-Zol RNA miniprep kit (Zymo).
Purified RNA was DNase treated with TURBO DNase (Life Technologies) and 3′
dephosphorylated/5′ phosphorylated with T4 Polynucleotide Kinase (New England
Biolabs). rRNA was eliminated using the bacterial Ribo-Zero rRNA removal kit (Illu-
mina). Next, RNA was treated with RNA 5′ polyphosphatase (Epicenter Bio) to con-
vert 5′-triphosphates to 5′-monophosphates for adaptor ligation. Samples were then
polyA tailed with E. coli Poly(A) polymerase (New England Biolabs), and a 5′ RNA
Illumina sequencing adaptor ligated to cellular RNA using T4 RNA Ligase 1 (ssRNA
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ligase) (New England Biolabs). RNA was reverse transcribed using AffinityScript
cDNA synthesis kit (Agilent Technologies) and an oligo-dT primer. cDNA was am-
plified with Herculase II polymerase (Agilent Technologies) and barcoded primers.
The prepared cDNA libraries were sequenced on a MiSeq (Illumina).
For RNA sequencing of native B. zoohelcum ATCC 43767, we repeated the
experiment with a modified protocol, omitting RNA 5′ polyphosphatase prior to 5′
adaptor ligation, to promote enrichment of processed transcripts originating from
the CRISPR array. For heterologous P. buccae ATCC 33574 RNA sequencing in E.
coli, we cloned the locus into pACYC184 (Table S1). Reads from each sample were
identified on the basis of their associated barcode and aligned to the appropriate
RefSeq reference genome using BWA (Li and Durbin, 2009). Paired-end alignments
were used to extract entire transcript sequences using Galaxy (https://usegalaxy.
org), and these sequences were analyzed using Geneious 8.1.8.
Nucleic Acid Preparation For in vitro synthesis of RNA, a T7 DNA fragment
must be generated. To create T7 DNA fragments for crRNAs, top and bottom strand
DNA oligos were synthesized by IDT. The top DNA oligo consisted of the T7 pro-
moter, followed by the bases GGG to promote transcription, the 30 nt target and
then direct repeat. Oligos were annealed together using annealing buffer (30 mM
HEPES pH 7.4, 100 mM potassium acetate, and 2 mM magnesium acetate). An-
nealing was performed by incubating the mixture for 1 min at 95∘C followed by a
−1∘C/minute ramp down to 23∘C. To create ssRNA targets, short targets (Trunc2,
3, 4) were synthesized as top and bottom strand oligos containing the T7 promoter.
For long ssRNA targets (E1, E2, S and L CRISPR Arrays), DNA primers (Table S1)
with a T7 handle on the forward primer were ordered and the DNA fragment was
amplified using PCR. T7 DNA constructs for RNA generation without body labeling
were incubated with T7 polymerase overnight (10-14 hr) at 30∘C using the HiScribe
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T7 Quick High Yield RNA Synthesis kit (New England Biolabs). Body-labeled con-
structs were incubated with Cyanine 5-UTP (Perkin Elmer) and incubated with T7
polymerase overnight at 30∘C using the HiScribe T7 High Yield RNA Synthesis kit
(New England Biolabs). For a complete list of crRNAs and target ssRNAs used in
this study see Table S1. 5′ end labeling was accomplished using the 5′ oligonucleotide
kit (VectorLabs) and with a maleimide-IR800 probe (LI-COR Biosciences). 3′ end
labeling was performed using a 3′ oligonucleotide labeling kit (Roche) and Cyanine
5-ddUTP (Perkin Elmer). RNAs were purified using RNA Clean and Concentrator
columnsTM-5 (Zymo Research). Body-labeled dsRNA substrates were prepared by
T7 DNA fragments for the bottom and top RNA strand. After synthesis, 1.3-fold
excess of non-labeled bottom strand ssRNA was added and re-annealed to ensure the
top strand would be annealed to a bottom strand by incubating the mixture for 1
min at 95∘C followed by a −1∘C/minute ramp down to 23∘C.
BzCas13b Protein Purification The mammalian codon-optimized gene for
Cas13b (B. zoohelcum) was synthesized (GenScript) and inserted into a bacterial
expression vector (6x His/Twin Strep SUMO, a pET based vector received as a gift
from Ilya Finkelstein) after cleaving the plasmid with the BamHI and NotI restriction
enzymes and cloning in the gene using Gibson Assembly Master Mix (New England
Biolabs). The BzCas13b expression construct (Table S2) was transformed into One
Shot BL21(DE3)pLysE (Invitrogen) cells. 25 mL of 6hr growing culture were inocu-
lated into 2 l of Terrific Broth 4 growth media (12 g/L tryptone, 24 g/L yeast extract,
9.4 g/L K2HPO4, 2.2 g/L KH2PO4, Sigma). Cells were then grown at 37∘C to a cell
density of 0.6 OD600, and then SUMO-BzCas13b expression was induced by supple-
menting with IPTG to a final concentration of 500 uM. Induced culture was grown
for 16-18 hr before harvesting cell paste, which was stored at −80∘C until subsequent
purification. Frozen cell paste was crushed and resuspended via stirring at 4∘C in
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500 mL of Lysis Buffer (50 mM NaH2PO4 pH 7.8, 400 mM NaCl) supplemented
with protease inhibitors (cOmplete, EDTA-free, Roche Diagnostics Corporation) and
1250 U of benzonase (Invitrogen). The resuspended cell paste was lysed by a LM20
microfluidizer at 18,000 psi (Microfluidics). Lysate was cleared by centrifugation at
10,000 g for 1 hr. Filtered lysate was incubated with StrepTactin Sepharose High
Performance (GE Healthcare Life Sciences) at 4∘C for 1 hr with gentle agitation, and
then applied to an Econo-column chromatography column (Bio-Rad Laboratories).
Resin was washed with Lysis Buffer for 10 column volumes. One column volume
of fresh Lysis Buffer was added to the column and mixed with 10 units of SUMO
protease (Invitrogen) and incubated overnight. The eluate was removed from the
column, SUMO cleavage was confirmed by SDS-PAGE and BlueFast protein stain-
ing (Eton Bioscience), and the sample was concentrated via Centrifugal Filter Unit
to 2 mL. Concentrated sample was loaded onto a HiTrap Heparin HP column (GE
Healthcare Life Sciences) via FPLC (AKTA Pure, GE Healthcare Life Sciences) and
eluted over a gradient with an elution buffer with salt concentration of 1.2 M. The
resulting fractions were tested for presence of BzCas13b protein by SDS-PAGE; frac-
tions containing BzCas13b were pooled, and concentrated via Centrifugal Filter Unit
to 1 mL. Concentrated sample was loaded a gel filtration column (HiLoad 16/600
Superdex 200, GE Healthcare Life Sciences) via FPLC (AKTA Pure, GE Healthcare
Life Sciences) with buffer 500 mM NaCl, 50 mM Tris-HCl pH 7.5, 1 mM DTT.
BzCas13b HEPNMutant Protein Purification Alanine mutants (Table S2) at
each of the HEPN catalytic residues were generated using the Q5 site-directed muta-
genesis kit (New England Biolabs) and transformed into One Shot BL21(DE3)pLysE
cells (Invitrogen). For each mutant, 1 L of Terrific Broth was used to generate cell
paste and all other reagents were scaled down accordingly. Protein purification was
performed using the same protocol as wild-type Cas13b.
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Nuclease Assay Nuclease assays were performed with equimolar amounts of end-
labeled or body-labeled ssRNA target, purified protein, and crRNA, for targeted
ssRNA cleavage. For CRISPR array cleavage, protein was supplied in a four times
molar excess of the CRISPR array. Reactions were incubated in nuclease assay buffer
(10 mM TrisHCl pH 7.5, 50 mM NaCl, 0.5 mM MgCl2, 20 U SUPERase Inhibitor
(ThermoFisher Scientific), 0.1% BSA). Reactions were allowed to proceed at 37∘C for
times specified in the figure legends. After incubation, samples were then quenched
with 0.8U of Proteinase K (New England Biolabs) for 15 min at 25∘C. The reactions
were mixed with equal parts of RNA loading dye (New England Biolabs) and dena-
tured at 95∘C for 5 min and then cooled on ice for 2 min. Samples were analyzed
by denaturing gel electrophoresis on 10% PAGE TBE-Urea (Invitrogen) run at 45∘C.
Gels were imaged using an Odyssey scanner (LI-COR Biosciences).
2.9.3 Data and Software Availability
Data Resources Data have been deposited in the following resources:
Next-Generation Sequencing for bacterial RNA-sequencing: https://www.
ncbi.nlm.nih.gov/bioproject/PRJNA358111
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Chapter 3
Biochemical and Genetic
Characterization of Cas13b
This chapter is derived in part from the Cas13b study published in Molecular Cell
(Smargon et al., 2017). Full citation is as follows:
Smargon, A.A.*, Cox, D.B.T.*, Pyzocha, N.K.*, Zheng, K., Slaymaker, I.M.,
Gootenberg, J.S., Abudayyeh, O.A., Essletzbichler, P., Shmakov, S., Makarova, K.S.,
Koonin, E.V. and Zhang, F. (2017). Cas13b Is a Type VI-B CRISPR-Associated
RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28.
Mol. Cell 65, 618−630.e7. (* denotes co-first authors)
Biochemical Contributions: Early on in the project, N.K.P., F.Z., and I
working together optimized the nucleic acid preparation and nuclease assay, and de-
signed and implemented experiments. This included carrying out the first successful
single spacer BzCas13b RNA cleavage experiment and following up with spacer tiling
experiments.
Genetic Contributions: With feedback from F.Z., I designed, implemented,
and analyzed the E. coli essential gene screen. D.B.T.C. and I working together
designed and implemented the kanamycin validation screen experiment, which I an-
alyzed. F.Z. and I working together designed the RFP-tagged protein fluorescent
imaging experiments, which I implemented.
3.1 Summary
Here we report the characterization of a class 2 sub-type, VI-B, which was discov-
ered through the computational approach described in Chapter 2, and demonstrate
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that the VI-B effector, Cas13b, is an RNA-guided RNase. Through a combination
of biochemical and genetic experiments, we show that Cas13b cleaves target RNA
and exhibits collateral RNase activity. Using an E. coli essential gene screen, we
demonstrate that Cas13b has a double-sided protospacer-flanking sequence and elu-
cidate RNA secondary structure requirements for targeting. We also find that Csx27
represses, whereas Csx28 enhances, Cas13b-mediated RNA interference. Characteri-
zation of these CRISPR systems creates opportunities to develop tools to manipulate
and monitor cellular transcripts.
3.2 Introduction
Functional class 2 CRISPR-Cas systems have been found to target both DNA and
RNA (Koonin et al., 2017). In order to achieve this nucleic acid targeting, they rely
on the complexing of their single effector with a programmable crRNA that includes
a direct repeat and spacer with reverse complementarity to its target protospacer.
In Chapter 2, through RNA sequencing we demonstrated that Cas13b processes its
associated pre-crRNA into a 66 nt mature crRNA, with a 30 nt 5′ spacer followed by
a 36 nt 3′ direct repeat.
After this proof-of-concept experiment, we set out to determine the ability of
Cas13b to target nucleic acids in an RNA-programmable fashion. In order to achieve
this goal, we designed and implemented a series of experiments, both genetic and
biochemical. In addition to many of the experimental techniques employed in Cas13a
studies (Abudayyeh et al., 2016; East-Seletsky et al., 2016), in the Cas13b study we
developed a few new assays—most notably the E. coli essential gene screen.
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3.3 An E. coli Essential Gene Screen Reveals Tar-
geting Rules for Cas13b
To validate the expected interference activity of the VI-B system and to determine
the targeting rules for the VI-B1 locus from B. zoohelcum, we developed an E. coli
essential gene screen (Figure 3-1A). For this negative selection screen, we generated a
library of 54,600 unique spacers tiled with single-nucleotide resolution over the coding
region of 45 monocistronic essential genes (Baba et al., 2006; Gerdes et al., 2003),
plus 60 nt into the 5′ and 3′ UTRs. We also included 1,100 randomly generated
non-targeting spacers to establish baseline activity (Table S3 and Table S4). We
then transformed this library with plasmids carrying bzcas13b (cas13b gene from B.
zoohelcum) and bzcsx27, just bzcas13b, or a control empty vector. After quality-
control filtering of all screened spacers, we found a statistically significant depletion
of targeting spacers over non-targeting spacers, indicating that Cas13b, alone or with
Csx27, can achieve nucleic acid interference (Figure 3-1B).
To assess the targeting rules for Cas13b, we established two spacer depletion
levels: strongly depleted (top 1% of depleted spacers) and safely depleted (spacers
depleted 5𝜎 above the mean depletion of the filtered non-targeting spacers). From
spacers passing the strongly depleted cutoff we derived sequence motifs qualitatively
identifying a double-sided protospacer flanking sequence (PFS) (Figure 3-1C) (Crooks
et al., 2004). Because each position in a sequence motif is assumed to be independent,
we developed a more quantitative, base-dependent PFS score defined as the ratio of
the number of safely depleted spacers to the number of all spacers with a given PFS,
normalized across all PFS scores (Figure 3-1D).
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Figure 3-1: Heterologous Expression of Cas13b Mediates Knockdown of
E. coli Essential Genes by a Double-Sided PFS. (A) Design of E. coli essential
gene screen to determine targeting rules of nucleic acid interference. (B) Manhattan
plots of mean spacer depletions mapped over 45 genes and aggregated across normal-
ized gene distance for either the full B. zoohelcum VI-B1 locus (left) or cas13b alone
(right), with non-targeting spacers in gray, safely depleted spacers (>5𝜎 above mean
depletion of non-targeting spacers) above blue line, and strongly depleted spacers
(top 1% depleted) above red line. For the full locus, 36,142 targeting spacers and 630
non-targeting spacers passed QC filter. Of the targeting, 367 are strongly depleted,
and 1,672 are safely depleted. For cas13b alone, 35,272 targeting spacers and 633
non-targeting spacers passed QC filter. Of the targeting, 359 are strongly depleted,
and 6,374 are safely depleted. (C) Weblogo of sequence motifs of strongly depleted
B. zoohelcum spacers. (D) Normalized PFS score matrix, where each score is the
ratio of number of safely depleted B. zoohelcum spacers to total number of spacers
for a given PFS, scaled so that maximum PFS score is 1. The 3′ PFS letters repre-
sent the RNA bases at the second and third 3′ PFS position. (E) Spacers targeting
kanamycin to validate PFS targeting rules of 5′ PFS (D) and 3′ PFS (NAN or NNA).
(F) Schematic of kanamycin validation screen for B. zoohelcum cas13b in E. coli.
(G) Results from kanamycin validation screen; spacer abundances versus control for
individual B. zoohelcum spacers, with abundances colored by type of spacer. See also
Figure 3-2, Table S2, Table S3, Table S4, and Table S5.
The normalized PFS scores revealed a 5′ PFS of D (A, U, or G) and 3′ PFS
of NAN or NNA, consistent for Cas13b with Csx27, as well as for Cas13b alone. To
validate these sequence-targeting rules, we performed an orthogonal depletion screen
with Cas13b alone, targeting the Kanamycin resistance gene (Figures 3-1E and 3-
1F). Four classes of spacers were created: non-targeting, targeting with both 5′ and 3′
PFS rules, targeting with only the 5′ or 3′ PFS rule, and targeting with neither rule.
Consistent with our findings from the E. coli essential gene screen, the combined
5′ and 3′ PFS spacers resulted in the highest Kanamycin sensitivity (Figures 3-1G
and 3-2A; Table S5).
In addition to experimenting with Cas13b from Bergeyella zoohelcum, we also
chose Prevotella buccae and Porphyromonas gingivalis due to our ability to order
genomic DNA for each organism readily from ATCC. We ended up exclusively se-
lecting B. zoohelcum and P. buccae, which conveniently corresponded to subtypes
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Figure 3-2: Targeting rule validation of BzCas13b and MS2 interference
assay of BzCas13b and PbCas13b. Related to Figures 3-1, 3-8, and 3-11.
(A) Spacers targeting kanamycin to validate PFS targeting rules of 5′PFS (D) and
3′ PFS (NAN or NNA) (left). Second kanamycin validation screen bioreplicate of
spacer abundances versus control for individual B. zoohelcum spacers, with abun-
dances colored by type of spacer (right). (B) Plaque drop assay with bioreplicates
for B. zoohelcum VI-B1 locus and cas13b, for P. buccae VI-B2 locus and cas13b, and
for P. buccae cas13b with pUC19, B. zoohelcum csx27, and P. buccae csx28.
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VI-B1 and VI-B2, respectively. When the E. coli essential gene screen was performed
with PgCas13b (Cas13b from P. gingivalis), targeting spacer depletions were indis-
tinguishable from non-targeting spacer depletions (Figure 3-3). As was confirmed by
additional genetic assays (unpublished data), PgCas13b has highly non-specific and
potentially toxic activity; even in non-specific crRNA conditions, it interfered with
any RNA targeted in our experiments. This corroborated result motivated us to focus
on B. zoohelcum and P. buccae.
BzCas13b proved to be easier to purify from bacteria than PbCas13b, and so
most Cas13b biochemical experiments were conducted with BzCas13b. We had also
hoped to observe how Csx27 and Csx28 might impact Cas13b targeting of RNA. Nei-
ther BzCsx27 nor PbCsx28, however, yielded any substantial purification, perhaps
due to toxicity in overexpression (unpublished data). Under these limiting circum-
stances, we explored the biochemical properties of Cas13b.
3.4 Cas13b Cleaves Single-Stranded RNA and Ex-
hibits Collateral Activity In Vitro
Based on the presence of the computationally predicted HEPN domains that function
as RNases in other CRISPR-Cas systems, including VI-A and some class 1 systems
(Abudayyeh et al., 2016; Kim et al., 2013; Sheppard et al., 2016; Staals et al., 2014),
we anticipated that Cas13b interferes with RNA. We confirmed this by demonstrat-
ing that purified Cas13b exclusively cleaves single-stranded RNA with both direct
repeat architectures (Figures 3-4A and 3-5A). We then validated the PFS targeting
rules biochemically, showing that a 5′ PFS of C greatly inhibits single-stranded RNA
cleavage (Figure 3-4B), whereas a 3′ PFS of NAN or NNA enhances this activity
(Figure 3-4C).
Other HEPN domain-containing CRISPR-Cas RNA-targeting systems, such as
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Figure 3-3: Raw E. coli essential gene screen data from three Cas13b
orthologs. Screen was conducted with Cas13b from Prevotella buccae ATCC 33574
(PB), Bergeyella zoohelcum ATCC 43767 (BZ), and Porphyromonas gingivalis ATCC
33277 (PG). Axes are the same as in Figure 3-1B (targeting spacers in blue, non-
targeting spacers in black).
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Csx1 from the type III-B CRISPR-Cas systems, preferentially cleave targets con-
taining specific single-stranded nucleotides (Sheppard et al., 2016). To determine
if Cas13b exhibits such a preference, we tested an RNA substrate with a variable
homopolymer loop outside of the spacer:protospacer duplex region (Figure 3-4D). A
heteropolymer loop consisting of alternating A then U was also tested (Figure 3-5B).
We observed cleavage at pyrimidine residues, with a strong preference for uracil. This
activity is abolished in the presence of EDTA (Figure 3-5C), suggesting a divalent
metal ion-dependent mechanism for RNA cleavage akin to that of a similar HEPN-
containing, class 2 effector protein, Cas13a (Abudayyeh et al., 2016; East-Seletsky et
al., 2016).
Given that Cas13a has also been reported to cleave RNA non-specifically once
activated by interaction with the target (“collateral effect”) (Abudayyeh et al., 2016;
East-Seletsky et al., 2016), we sought to test the ability of Cas13b to cleave a second,
non-specific substrate following target cleavage. Using an in vitro assay similar to the
one we previously used with Cas13a (Abudayyeh et al., 2016), we incubated Cas13b-
crRNA complexes with both a target and non-target RNA substrate. We observed
collateral cleavage of the non-targeted RNA, but only in the presence of the target
RNA (Figure 3-4E).
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Figure 3-4: Cas13b Is a Programmable Single-Stranded RNase with Col-
lateral Activity. (A) Schematic showing the RNA secondary structure of the
cleavage target in complex with a targeting 30 nt spacer connected to short direct
repeat (top). Denaturing gel demonstrating short direct repeat and long direct re-
peat crRNA-mediated ssRNA cleavage (bottom). Reactions were incubated for 10
min. The ssRNA target is 5′ labeled with IRDye 800. Three cleavage sites are ob-
served. (B) Schematic showing three numbered protospacers for each colored 5′ PFS
on a body-labeled ssRNA target (top); denaturing gel showing crRNA-guided ssRNA
cleavage activity demonstrating the requirement for a D 5′ PFS (not C) (bottom).
Reactions were incubated for 60 min. crRNAs correspond to protospacer numbered
from the 5′ to the 3′ end of the target. Gel lane containing RNA ladder is not shown.
(C) Schematic of a body-labeled ssRNA substrate being targeted by a crRNA (top).
The protospacer region is highlighted in blue, and the orange bars indicate the 5′ PFS
and 3′ PFS sequences. The orange letters represent the altered sequences in the exper-
iment. Denaturing gel showing crRNA-guided ssRNA cleavage activity after 60 min
of incubation, with the 5′ PFS tested as A and the 3′ PFS tested as ANN (bottom).
The orange 3′ PFS letters represent the RNA bases at the second and third 3′ PFS
position within each target ssRNA. Gel lane containing RNA ladder is not shown.
Dashed line indicates two separate gels shown side by side. (D) Schematic showing
the secondary structure of the body-labeled ssRNA targets used in the denaturing
gel. The variable loop of the schematic (represented as N5) is substituted with five
monomers of the variable loop base in the gel (top). Denaturing gel showing cleavage
bands of the homopolymer variable loop base (bottom). The targets were incubated
for 30 min. Dashed line indicates seprate gel images (shown in Figure 3-12B). Gel
lane containing RNA ladder is not shown. (E) Denaturing gel showing BzCas13b
collateral cleavage activity after 30 min of incubation, with schematic of cleavage ex-
periment to the right. Two crRNAs (A and B) target substrate 1 (1A and 1B) or
substrate 2 (2A and 2B). Gel lane containing RNA ladder is not shown. Dashed line
indicates two separate gels shown side by side. See also Figures 2-9 and 3-5 and Table
S1.
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Figure 3-5: Cas13b cleaves and binds to single-stranded RNA. Related to
Figures 3-4 and 3-8. (A) Denaturing gels demonstrating no cleavage of dsRNA,
ssDNA, or dsDNA by BzCas13b with either the short DR or long DR. Reactions
were incubated for 10 minutes, the same amount of time which results in robust
ssRNA cleavage for this target and crRNA pair. The ssDNA and top strand of the
dsDNA target is 5′ labeled with IRDye 800. The dsRNA target is body labeled.
Gel lane containing RNA ladder not shown. (B) Denaturing gel showing cleavage
bands from the variable loop target as shown in Figure 3-4D. The U/A heteropolymer
consists of the N5 variable loop of alternating U and A residues (5′ AUAUA 3′). (C)
ssRNA cleavage requires BzCas13b and a targeting crRNA, and this cleavage activity
is abolished by addition of EDTA. Gel lane containing RNA ladder not shown. (D)
Denaturing gel showing PbCas13b cleavage activity of an ssRNA targeted substrate.
The ssRNA is 5′ labeled with IRDye 800 and incubated for 30 minutes. Gel lane
containing RNA ladder not shown. (E) EMSA gels that were used to quantify the𝐾𝐷
of the WT and mutant BzCas13b proteins, using an on-target crRNA complementary
to the targeted ssRNA. (F) EMSA gel of WT BzCas13b with an off-target crRNA.
The off-target crRNA is non-complementary to the targeted ssRNA.
Obtaining convincing Cas13b biochemical data took months of optimization.
Initially our in vitro cleavage RNA gels looked inefficient, blurry, and wholly unin-
terpretable (unpublished data). Then, upon adding certain reagents to our chemical
reactions during a combined pH-[NaCl] optimization, suddenly the gels came into
focus (Figure 3-6). In this critical chemical reaction, we added DTT to prevent disul-
fide bond formation, BSA to prevent Cas13b binding to the test tube, and RNase
inhibitor to reduce RNA degradation from contaminating RNases. While all reagents
improved the quality of the gel, RNase inhibitor had the highest marginal benefit.
Before the E. coli essential gene screen had revealed the targeting rules of
Cas13b, we attempted to deduce them biochemically. Due to the collateral effect,
such biochemical screens were inconclusive upon sequencing (all protospacer flanking
sequences cut with equal probability), and we were left with single spacer-variable
protospacer RNA cleavage assays (Figure 3-6). To overcome this impasse somewhat,
we performed randomized single spacer-single protospacer tiling cleavage assays (Fig-
ure 3-7A). Regrettably, data at such low sample size did not reveal any clear PFS.
Upon later inspection, data from spacers that successfully cleaved did corroborate the
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100ng target, 1:1:1 molar ratio target: crRNA: protein
20 min incubation @37C, 1mM DTT 0.1% BSA, 10% RNAse inhibitor
10mM Tris-HCl pH 7.5
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Figure 3-6: Earliest conclusive evidence of single spacer RNA cleavage by
Cas13b. BzCas13b in vitro cleavage assay with single spacer against body-labeled
target with a protospacer of 𝑁7 complexity on the 5′ PFS. This optimization over
various concentrations of NaCl was the first time DTT, BSA, and RNase inhibitor
were used in biochemical reactions. Experimental conditions are as stated in the
figure (n.s.: non-specific crRNA).
double-sided PFS as ascertained by the E. coli essential gene screen (Figure 3-7B).
3.5 Cas13b Shows Robust HEPN-Dependent Inter-
ference and Is Repressed by Csx27 Activity
To validate RNA interference in vivo, we assayed interference against the lytic, single-
stranded RNA bacteriophage MS2, whose life cycle contains no DNA intermediates.
We performed an MS2 drop plaque assay at serial dilutions of phage for both bzcas13b
with bzcsx27 and for bzcas13b alone with three spacers targeting the MS2 genome, two
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Guides that cut:
Guide Index Left Flank Target Right Flank Target Position
1 CCTGGGGCACAAGCTGGAGTACAACTACAA CAGCCACAACGTCTATATCATGGCCGACAA GCAGAAGAACGGCATCAAGGTGAACTTCAA 114
4 ATCGAGCTGAAGGGCATCGACTTCAAGGAG GACGGCAACATCCTGGGGCACAAGCTGGAG TACAACTACAACAGCCACAACGTCTATATC 73
8 AACTACAACAGCCACAACGTCTATATCATG GCCGACAAGCAGAAGAACGGCATCAAGGTG AACTTCAAGATCCGCCACAACATCGAGGAC 136
9 TGAAGGGCATCGACTTCAAGGAGGACGGCA ACATCCTGGGGCACAAGCTGGAGTACAACT ACAACAGCCACAACGTCTATATCATGGCCG 80
10 ACATCCTGGGGCACAAGCTGGAGTACAACT ACAACAGCCACAACGTCTATATCATGGCCG ACAAGCAGAAGAACGGCATCAAGGTGAACT 110
13 ACGTCTATATCATGGCCGACAAGCAGAAGA ACGGCATCAAGGTGAACTTCAAGATCCGCC ACAACATCGAGGACGGCAGCGTGCAGCTCG 152
16 GCATCGAGCTGAAGGGCATCGACTTCAAGG AGGACGGCAACATCCTGGGGCACAAGCTGG AGTACAACTACAACAGCCACAACGTCTATA 71
19 CAACTACAACAGCCACAACGTCTATATCAT GGCCGACAAGCAGAAGAACGGCATCAAGGT GAACTTCAAGATCCGCCACAACATCGAGGA 135
Guides that didn't visibly cut:
Guide Index Left Flank Target Right Flank Target Position
2 GTACAACTACAACAGCCACAACGTCTATAT CATGGCCGACAAGCAGAAGAACGGCATCAA GGTGAACTTCAAGATCCGCCACAACATCGA 132
3 GGCAACATCCTGGGGCACAAGCTGGAGTAC AACTACAACAGCCACAACGTCTATATCATG GCCGACAAGCAGAAGAACGGCATCAAGGTG 106
5 GGAGTACAACTACAACAGCCACAACGTCTA TATCATGGCCGACAAGCAGAAGAACGGCAT CAAGGTGAACTTCAAGATCCGCCACAACAT 129
6 CAAGCAGAAGAACGGCATCAAGGTGAACTT CAAGATCCGCCACAACATCGAGGACGGCAG CGTGCAGCTCGCCGACCACTACCAGCAGAA 171
7 AAGAACGGCATCAAGGTGAACTTCAAGATC CGCCACAACATCGAGGACGGCAGCGTGCAG CTCGCCGACCACTACCAGCAGAACACCCCC 178
11 TACAACAGCCACAACGTCTATATCATGGCC GACAAGCAGAAGAACGGCATCAAGGTGAAC TTCAAGATCCGCCACAACATCGAGGACGGC 139
12 AGCTGGAGTACAACTACAACAGCCACAACG TCTATATCATGGCCGACAAGCAGAAGAACG GCATCAAGGTGAACTTCAAGATCCGCCACA 125
14 ACGGCAACATCCTGGGGCACAAGCTGGAGT ACAACTACAACAGCCACAACGTCTATATCA TGGCCGACAAGCAGAAGAACGGCATCAAGG 104
15 TATATCATGGCCGACAAGCAGAAGAACGGC ATCAAGGTGAACTTCAAGATCCGCCACAAC ATCGAGGACGGCAGCGTGCAGCTCGCCGAC 157
17 TGGAGTACAACTACAACAGCCACAACGTCT ATATCATGGCCGACAAGCAGAAGAACGGCA TCAAGGTGAACTTCAAGATCCGCCACAACA 128
18 GCAACATCCTGGGGCACAAGCTGGAGTACA ACTACAACAGCCACAACGTCTATATCATGG CCGACAAGCAGAAGAACGGCATCAAGGTGA 107
20 TTCAAGGAGGACGGCAACATCCTGGGGCAC AAGCTGGAGTACAACTACAACAGCCACAAC GTCTATATCATGGCCGACAAGCAGAAGAAC 94
Figure 3-7: Earliest conclusive, comprehensive (𝑁 > 2) evidence of single
spacer-single protospacer RNA cleavage by Cas13b. (A) BzCas13b in vitro
cleavage assay with randomized spacer tiling along body-labeled target RNA from
EGFP, which would form the basis of Figure 3-4B. Experimental conditions are as
stated in the figure (n.s.: non-specific crRNA). (B) Corresponding sequences of pro-
tospacer (‘target’) and 5′ (‘left’) and 3′ (‘right’) flanking sequences, along with their
indices and positions along the target RNA. In retrospect, these data (cutting vs.
non-cutting by index) are compatible with the complex double-sided PFS of Cas13b.
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at the lys-rep interface and one in rep, as well as one non-targeting spacer (Figure 3-
8A). We observed substantial reduction in plaque formation for all targeting spacers
compared to the non-targeting spacer, confirming sequence-specific RNA targeting by
VI-B1 systems. (Figures 3-8A and 3-2B; Table S6). Notably, the presence of bzcsx27
weakened RNA interference by bzcas13b for all three targeting spacers.
To confirm the lack of DNA interference in vivo, we adapted a previously es-
tablished plasmid interference assay (Zetsche et al., 2015) with a protospacer placed
either in-frame at the 5′ end of the bla ampicillin-resistance gene (transcribed target)
or upstream of the bla gene promoter on the opposite strand (non-transcribed target).
Bacteria co-transformed with bzcas13b and spacer as well as the non-transcribed tar-
get plasmid survived at a rate comparable to that of co-transformation of the same
target with the empty vector on dual antibiotic selection. For bacteria co-transformed
with the transcribed target, the colony-forming unit rate under dual antibiotic se-
lection was reduced by approximately two orders of magnitude in the presence of
bzcas13b, corroborating that Cas13b exclusively targets RNA in vivo (Figure 3-8B).
We next tested if predicted catalytic residues in the HEPN domains were respon-
sible for RNA cleavage by Cas13b. Three HEPN mutants were generated by replacing
the conserved catalytic arginines and histidines in the two HEPN domains with ala-
nines (R116A/H121A, termed domain 1 [D1]; R1177A/H1182A, termed domain 2
[D2]; and R116A/H121A/R1177A/H1182A, termed quadruple [Q]) (Figure 2-9). All
mutants lacked observable cleavage activity (Figure 3-8C), yet retained RNA bind-
ing capacity in vitro (Figures 3-8D and 3-5E). The wild-type and all three HEPN
mutant Cas13b proteins showed comparable binding affinities for a single-stranded
target RNA substrate, with 𝐾𝐷 values ranging from 27 nM to 42 nM (Figures 3-8D
and 3-5E; Table S7). The 𝐾𝐷 for off-target binding was found to be greater than
188nM (Figure 3-5F).
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Figure 3-8: HEPN Domains Mediate RNA Cleavage by Cas13b, the Activ-
ity of Which Is Repressed by Csx27. (A) Protospacer design for MS2 phage drop
plaque assay to test RNA interference (left); drop plaque assay for full B. zoohelcum
VI-B1 locus (center) and bzcas13b (right). (B) DNA interference assay schematic
(top) and results (bottom). A target sequence is placed in-frame at the start of
the transcribed bla gene that confers ampicillin resistance or in a non-transcribed
region on the opposite strand of the same target plasmid. Target plasmids were
co-transformed with bzcas13b plasmid or empty vectors conferring chloramphenicol
resistance and plated on double selection antibiotic plates. (C) Schematic (top) and
denaturing gel (bottom) showing ssRNA cleavage activity of WT and HEPN mutant
BzCas13b. The protein and targeting crRNA complexes were incubated for 10 min.
Gel lane containing RNA ladder is not shown. (D) Electrophoretic mobility shift
assay (EMSA) graph showing the affinity of BzCas13b proteins and targeting crRNA
complex to a 5′ end-labeled ssRNA. EMSA was performed with supplemental EDTA
to reduce any cleavage activity. (E) Quantification of MS2 phage drop plaque as-
say with B. zoohelcum wild-type and Q (R116A/H121A/R1177A/H1182A) mutant
Cas13b. See also Figures 2-9− 3-5, Table S1, Table S2, Table S6, and Table S7.
We confirmed the involvement of the HEPN domains in RNA interference in
vivo, finding ∼5.5 orders of magnitude decrease in resistance to MS2 phage in the
quadruple HEPN mutants versus wild-type Cas13b (Figures 3-8E and 3-2B). Inter-
estingly, quadruple mutant Cas13b with spacers 2 and 3 still showed weak phage
resistance, potentially due to catalytically inactive Cas13b binding to phage genomic
RNA, leading to reduced phage replication.
3.6 Computational Modeling Predicts Additional
Targeting Rules Governing Cas13b
Our sequence-based targeting results from the E. coli essential gene screen implied
the existence of additional RNA-targeting rules beyond the PFS (only 18% of spacers
were safely depleted for bzcas13b; from the PFS rules alone, the expected value would
be 33%). Given that RNA targets contain a variety of secondary structures, we
sought to determine how RNA accessibility impacts targeting. Using the Vienna
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RNAplfold method (Bernhart et al., 2006), which has been successfully employed
to predict RNAi efficiency (Tafer et al., 2008) (Figure 3-9A), we trained and tested
an RNA accessibility model for spacer efficiency on our screen data and found that
RNA accessibility matters the most in the protospacer region most distal to the direct
repeat of the crRNA (Figures 3-9B and 3-9C).
Given the collateral activity observed in vitro, we examined our screen data
for indications of non-specific RNA cleavage by Cas13b. To this end, we calculated
the empirical cumulative distribution functions of safely depleted spacers aggregated
across all essential genes from the 5′ UTR into the gene and from the 3′ UTR into the
gene (Figure 3-9D). Because cleavage closer to the 5′ UTR is more likely to disrupt
gene function, without non-specific RNase activity we would expect an overrepre-
sentation of spacers in the 5′ UTR and an underrepresentation in the 3′ UTR. By
contrast, in the presence of collateral activity a nearly uniform distribution would
be expected. From our screen data, we observed a marginal underrepresentation of
spacers in the 3′ UTR compared to a uniform distribution, suggesting that collateral
activity may occur in vivo.
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Figure 3-9: Efficient RNA Targeting by Cas13b Is Correlated with Local
RNA Accessibility. (A) Methodology of secondary structure-mediated spacer ef-
ficiency analysis of E. coli essential gene screen data with Vienna RNAplfold. (B)
Optimization of top 1 accuracy (computationally predicted most accessible spacer
matches the top experimentally depleted spacer) and top 3 accuracy (computation-
ally predicted top spacer falls in top three experimentally depleted spacers) on ran-
domly selected B. zoohelcum training dataset using RNAplfold, first with u start and
u end, and then with W and L. (C) Performance of optimized RNAplfold model
on randomly selected B. zoohelcum testing dataset (48 cohorts for full B. zoohelcum
VI-B1 locus, 56 cohorts for bzcas13b) against 106 Monte Carlo simulations: empirical
p values from left to right of 3e-6, 1e-6, 8.7e-3, and 6e-6. (D) Empirical cumulative
distribution function of safely depleted B. zoohelcum spacers over all genes from 5′
UTR into gene and from 3′ UTR into gene. Yellow line separates UTR and gene, red
line is theoretical cumulative distribution function of uniformly distributed spacers,
and blue line is empirical cumulative distribution of safely depleted B. zoohelcum
spacers. See also Table S3 and Table S4.
3.7 CRISPR-Cas13b Effectors Are Differentially
Regulated by Csx27 and Csx28
Having characterized Cas13b alone (VI-B), we sought to characterize the VI-B1 and
V-B2 subtypes in the presence of Csx27 and Csx28, respectively. Both putative
accessory proteins were predicted to contain one or more transmembrane segments
(Figure 3-10A) (Möller et al., 2001). However, Csx27 of Bergeyella zoohelcum and
Csx28 of Prevotella buccae tagged with RFP at either the N or the C terminus did not
show membrane localization when expressed in E. coli (Figure 3-10B). In addition to
the predicted hydrophobic domains, analysis of the multiple sequence alignment of
Csx28 proteins indicated the presence of a divergent HEPN domain (Figure 2-6C).
This property in particular led us to believe that Csx27 and/or Csx28 might affect
the RNA-targeting capability of Cas13b.
To determine how the established RNA targeting rules generalize across the
subtype VI-B systems from diverse bacteria, we characterized the subtype VI-B2
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Figure 3-10: Predicted transmembrane domains of Csx27 and Csx28 not
validated experimentally. Related to Figure 2-5. (A) Transmembrane domain
prediction in Csx27 of B. zoohelcum and Csx28 of P. buccae using TMHMM v2. (B)
N- and C-terminally fused RFP imaging of Csx27 of B. zoohelcum and Csx28 of P.
buccae.
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locus from P. buccae. RNA sequencing of the CRISPR array revealed processing
effectively identical to that of B. zoohelcum, excluding the long crRNA (Figure 3-
12A). The E. coli essential gene screen with pbcas13b and pbcsx28 or pbcas13 alone
led to the identification of a PFS matrix similar to that of B. zoohelcum, with certain
PFSs disfavored (Figures 3-11A, 3-12B, and 3-12C). Similar to BzCas13b, PbCas13b
was found to cleave targeted single-stranded RNA in vitro (Figure 3-5D). As with
bzcsx27, the presence of pbcsx28 did not appreciably alter the PFS. We also repeated
the secondary structure analysis with pbcas13b, and a comparable RNAplfold model
applied (Figure 3-12D). Strikingly, in these experiments the safely depleted spacers for
pbcas13b alone were highly biased to the beginning of the 5′ UTR of genes, suggestive
of inhibited or more spatially localized RNase activity in the absence of pbcsx28
(Figure 3-12E). We further explored the apparent reduced activity of pbcas13b alone
relative to the respective full CRISPR-Cas locus using the MS2 phage drop plaque
assay and found that pbcsx28 enhances MS2 phage interference by up to four orders
of magnitude (Figures 3-11B and 3-2B). The differential ability of csx27 to repress
and csx28 to enhance cas13b activity generalizes across thousands of spacers in the
E. coli essential gene screen (Figure 3-11C), highlighting the distinctive regulatory
modes of the two variants of subtype VI-B CRISPR-Cas systems.
To investigate the ability of the small accessory proteins to modulate Cas13b
activity further, we tested if Csx27 can also repress PbCas13b using the MS2 drop
plaque assay. Cells co-transformed with pbcas13b and bzcsx27 expression plasmids
exhibited a 105-fold reduction in interference activity relative to pbcas13b expression
plasmid and pUC19 empty vector, indicating that Csx27 exerts an inhibitory effect
on PbCas13b (Figures 3-11D and 3-2B). The ability of Csx27 to modulate the inter-
ference activity of BzCas13b and PbCas13b suggests that it is a modular protein that
can function across multiple VI-B loci.
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Figure 3-11: Class 2 Type VI-B Systems Are Differentially Regulated
across Two Loci by Csx27 and Csx28. (A) Normalized PFS matrix for P.
buccae VI-B2 locus (top) and pbcas13b (bottom). The 3′ PFS letters represent the
RNA bases at the second and third 3′ PFS position. (B) MS2 drop plaque assay
for full P. buccae VI-B2 locus (top) and pbcas13b (bottom). (C) Spacer depletions
of bzcas13b with and without bzcsx27 (brown), as compared to pbcas13b with and
without pbcsx28 (gold). (D) Fold resistance to MS2 infection for cells co-transformed
with pbcas13b and the indicated csx expression plasmid. See also Figures 3-2 and 3-12,
Table S2, Table S3, Table S4, and Table S6.
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Figure 3-12: RNA-targeting of P. buccae VI-B2 CRISPR locus. Related
to Figure 3-11. (A) RNA-Sequencing of heterologously expressed VI-B2 locus from
P. buccae ATCC 33574 in E. coli. (B) Manhattan plots of spacer depletions mapped
over 45 genes and aggregated across normalized gene distance for full P. buccae VI-
B2 locus (left) and cas13b (right), with non-targeting spacers in gray, safely depleted
(>5𝜎 above mean depletion of non-targeting spacers) spacers above blue line, and
strongly depleted (top 1% depleted) spacers above red line. For the full locus, 36,141
targeting spacers and 859 non-targeting spacers passed QC filter. Of the targeting,
370 are strongly depleted and 8065 are safely depleted. For cas13b alone, 41,126
targeting spacers and 824 non-targeting spacers passed QC filter. Of the targeting,
419 are strongly depleted and 3295 are safely depleted. (C) Sequence weblogos of
strongly depleted P. buccae spacers, revealing double-sided PFS (protospacer flank-
ing sequence). (D) Performance of optimized RNAplfold model (W=240, L=180,
u start=16, u end=30) on randomly selected P. buccae testing dataset (41 cohorts
for full P. buccae VI-B2 locus, 40 cohorts for pbcas13b) against 106 Monte Carlo
simulations: empirical P-values from left to right of 3.3e-2, 2.7e-3, 3.9e-3, 1.5e-5. (E)
Empirical cumulative distribution function of safely depleted P. buccae spacers over
all genes from 5′ UTR into gene and from 3′ UTR into gene. Yellow line separates
UTR and gene, red line is theoretical cumulative distribution function of uniformly
distributed spacers, and blue line is empirical cumulative distribution of safely de-
pleted P. buccae spacers.
3.8 Discussion
Here we describe two RNA-targeting CRISPR class 2 systems of subtype VI-B (VI-B1
and VI-B2), containing the computationally discovered RNA-guided RNase Cas13b.
Type VI-B systems show several notable similarities to the recently characterized VI-
A system. The single protein effectors of both systems cleave single-stranded RNA
via HEPN domains, process their CRISPR arrays independent of the HEPN domains,
and exhibit collateral RNase activity. Cas13b proteins, however, show only limited
sequence similarity to Cas13a, and the common ancestry of the two type VI subtypes
remains uncertain. Furthermore, the type VI-B systems differ from VI-A in several
other novel ways, including the absence of both cas1 and cas2, which are involved in
spacer acquisition in other CRISPR-Cas systems (Mohanraju et al., 2016). The VI-B
CRISPR arrays contain multiple spacers that differ among closely related bacterial
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strains, suggesting that acquisition does occur, either autonomously or possibly in
trans, by recruiting Cas1 and Cas2 encoded in other CRISPR-Cas loci from the same
genome. In trans utilization of adaptation modules of other CRISPR-Cas systems is
compatible with the finding that the great majority of type VI-B systems co-occur
in the same bacterial genome as other CRISPR-Cas loci that include cas1 and cas2
genes; conceivably, the three VI-B-carrying genomes that lack adaptation modules
have lost them recently. Additionally, VI-B systems differ from VI-A systems by
the presence of the small accessory proteins Csx27 (VI-B1 systems) and Csx28 (VI-
B2 systems), which exert opposing regulatory effects on Cas13b activity. The near
ubiquity and mutual exclusivity of these accessory proteins in CRISPR-Cas13b loci
is notable and quite intriguing.
Repression of Cas13b by Csx27 in VI-B1 systems could be part of an important
regulatory mechanism of phage interference. The ability of Csx27 to repress Cas13b
activity may be a general property, as we found that it can also repress PbCas13b
(subtype VI-B2). In the case of type VI-B2 systems, Csx28 might enhance the collat-
eral activity of Cas13b to inactivate numerous transcripts of invading bacteriophages
or to promote programmed cell death. Both Csx27 and Csx28 contain predicted long,
hydrophobic 𝛼 helices that might enable them to interact physically with Cas13b, but
this remains to be determined. We did not find homologs of Csx27 or Csx28 encoded
in any CRISPR-Cas loci other than type VI-B loci, suggesting that these proteins
might function in tight association with Cas13b.
As with previously characterized class 2 CRISPR-Cas effectors, such as Cas9
and Cpf1, there is enormous potential to harness Cas13b for use as a molecular
tool (Cong et al., 2013; Mali et al., 2013; Wright et al., 2016). A comprehensive
understanding of the factors that affect target selection is essential to the success of
any such tools, particularly those that target RNA, where secondary structure will
likely impact activity. We therefore developed a novel E. coli essential gene screen
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to explore the targeting rules of Cas13b more fully. This E. coli screen offers several
advantages by increasing the number of guides testable in a single experiment to
explore how diverse spacer and flanking sequences may affect Cas13b activity. This
screen revealed a double-sided PFS in VI-B systems, which may give insight into
Cas13b protein-RNA interactions and could help improve specificity by expanding
sequence targeting constraints (Ran et al., 2015).
The characterization of Cas13b and other RNA-targeting CRISPR systems
raises the prospect of a suite of precise and robust in vivo RNA manipulation tools
for studying a wide range of biological processes (Abil and Zhao, 2015; Filipovska
and Rackham, 2011; Mackay et al., 2011). The ability of Cas13b to process its own
CRISPR array could be extended to multiplex transcriptome engineering. In addi-
tion, the VI-B functional long direct repeats could be altered to incorporate stem
loops akin to the Cas9-SAM system (Konermann et al., 2015). Like Cas9 and Cpf1,
Cas13a and Cas13b may be utilized for complementary applications in science and
technology.
3.9 Methods
3.9.1 Experimental Model and Subject Details
E. coli E. coli was grown in LB at 37∘C at 250 rpm overnight.
One Shot Stbl3 E. coli E. coli was grown in LB at 37∘C at 250 rpm overnight.
NEB 10-Beta Competent E. coli (High Efficiency) NEB 10-beta Competent
E. coli was transformed on LB agar at 37∘C overnight.
MegaX DH10B T1R Electrocompetent Cells MegaX DH10B T1R Electro-
competent E. coli was transformed on LB agar at 37∘C overnight.
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3.9.2 Method Details
E. coli Essential Gene Screen Experiment The intersection of two E. coli
DH10B strain essential gene studies (Baba et al., 2006; Gerdes et al., 2003) was
taken, and further pared down to 45 genes by only selecting genes exclusive to their
respective operons (Table S3). Over these 45 genes 54,600 spacers were designed
to tile at single resolution across the coding region, as well as to extend 60 nt into
the 5′ UTR and 3′ UTR. In addition, 1100 non-targeting, pseudorandomly generated
spacers with no precise match to the E. coli DH10B strain genome were added to
the library as a non-targeting negative control. The library of spacers (Table S4) was
cloned into a B. zoohelcum or P. buccae direct repeat-spacer-direct repeat backbone
containing a chloramphenicol resistance gene using Golden Gate Assembly (NEB)
with 100 cycles, and then transformed over five 22.7cm x 22.7cm chloramphenicol LB
Agar plates. Libraries of transformants were scraped from plates and DNA was ex-
tracted using the Macherey-Nagel Nucleobond Xtra Midiprep Kit (Macherey-Nagel).
50 ng of library plasmid and equimolar gene plasmid containing an ampicillin re-
sistance gene (bzcas13b, bzcas13b & bzcsx27, pbcas13b, pbcas13b & pbcsx28, empty
vector pBR322) (Table S2) were transformed into MegaX DH10B T1R Electrocomp
Cells (ThermoFisher) according to manufacturer’s protocol, with four separate 22.7cm
x 22.7cm carbenicillin-chloramphenicol LB Agar plates per bioreplicate, and three
bioreplicates per condition (twelve transformations total per condition). Eleven hours
post-transformation, libraries of transformants were scraped from plates and DNA ex-
tracted using the Macherey-Nagel Nucleobond Xtra Maxiprep Kit (Macherey-Nagel).
E. coli Essential Gene Screen Analysis Prepared DNA libraries were sequenced
on a NextSeq (Illumina), with reads mapped to the input library of spacers. Spacer
depletions were calculated as the read abundance of a spacer in the empty vector
condition divided by read abundance in each gene plasmid condition. Mean deple-
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tions over three bioreplicates were calculated. We imposed a two-step quality-control
filter on the data: a maximum coefficient of variation of 0.2 for depletion over three
bioreplicates, and a minimum spacer read abundance of 1/3𝑁 in each bioreplicate,
where 𝑁 = 55,700. Weblogos of the strongly depleted (top 1% depleted) spacers were
generated (Crooks et al., 2004), and from each identified PFS, heatmaps of the ratio
of safely depleted (> 5𝜎 above mean depletion of non-targeting spacers) spacers to
all spacers in the screen were generated. For spatial analysis via empirical cumulative
distribution functions, safely depleted spacers were aggregated across the first or last
250 nt of genes.
For secondary structure analysis, we utilized the RNA accessibility model from
Vienna RNAplfold (Bernhart et al., 2006). RNAplfold calculates through a moving
average of RNA folds the probability that a region u of RNA is unpaired given
its cis sequence context in a four-parameter model, where W is the moving average
window length in nucleotides, L is the maximum permissible pairing distance between
nucleotides in the window, and ustart and uend are the start and end of the region u,
respectively. To apply this model to our data, we separated spacers from our E. coli
essential gene screen into training/testing cohorts of five or more, each represented
by a unique permissible PFS and gene and containing at least one spacer in the
top 2% of depleted spacers from the screen (to enhance predictive signal). We then
randomly divided these cohorts into a training set (80%) and a testing set (20%). For
optimizing a secondary structure-mediated model of efficient spacer design we selected
as objective functions top 1 or top 3 accuracy, the percent of cohorts for which the
top spacer is accurately predicted or falls in the top 3 depleted spacers in a cohort,
respectively. We optimized the two objective functions on the training dataset, first
by fixing W and L while varying ustart and uend, then by fixing ustart and uend and
varyingW and L (Figure 3-4B). In the case of bzcas13b with bzcsx27, as well as that of
bzcas13b alone, the optimized parameters were found to be approximately W = 240,
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L = 180, ustart = 16, and uend = 30. We gauged the performance of this RNAplfold
model relative to 106 Monte Carlo simulations performed on the testing dataset and
found empirical 𝑃 -values of less than 1e-2 for top 1 accuracy, and less than 1e-5 for
top 3 accuracy. Similar predictive power applied to pbcas13b with pbcsx28, as well as
to pbcas13b alone.
Kanamycin Validation Screen Experiment A total of 160 kanamycin-targeting
spacers was selected, 42 of which contain both PFS rules, 47 of which contain one
rule, and 71 of which contain no rules, to which 162 non-targeting control spacers
were added (Table S5). The library of spacers was cloned into either a bzcas13b and
B. zoohelcum direct repeat-spacer-direct repeat backbone or simply a B. zoohelcum
direct repeat-spacer-direct repeat backbone containing a chloramphenicol resistance
gene using Golden Gate Assembly (NEB) with 100 cycles, and then transformed over
one 22.7cm x 22.7cm carbenicillin LB Agar plate. The two cloned library plasmids
were then re-transformed with over a 22.7cm x 22.7cm chloramphenicol LB Agar plate
or a 22.7cm x 22.7cm kanamycin-chloramphenicol LB Agar plate. Libraries of trans-
formants were scraped from plates and DNA extracted using the QIAGEN Plasmid
Plus Maxi Kit (QIAGEN). 100 ng of library DNA and 100 ng of pMAX-GFP (Lonza),
containing a kanamycin resistance gene were added to 50 uL of chemically competent
10-beta cells (NEB) and transformed according to the manufacturer’s protocol.
Kanamycin Validation Screen Analysis Prepared DNA libraries were se-
quenced on a NextSeq (Illumina), with reads mapped to the input library of spacers.
For normalizing the abundance of spacers of two separate clonings, the corrected ex-
perimental read abundance of a given spacer was calculated as the read abundance
of that spacer in the bzcas13b plasmid (kanamycin-chloramphenicol transformation)
multiplied by the ratio of the read abundance ratio of that spacer in the non-bzcas13b
plasmid (chloramphenicol-only transformation) to the read abundance ratio of that
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spacer in the bzcas13b plasmid (chloramphenicol-only transformation).
Nucleic Acid Preparation For in vitro synthesis of RNA, a T7 DNA fragment
must be generated. To create T7 DNA fragments for crRNAs, top and bottom strand
DNA oligos were synthesized by IDT. The top DNA oligo consisted of the T7 pro-
moter, followed by the bases GGG to promote transcription, the 30 nt target and
then direct repeat. Oligos were annealed together using annealing buffer (30 mM
HEPES pH 7.4, 100 mM potassium acetate, and 2 mM magnesium acetate). An-
nealing was performed by incubating the mixture for 1 min at 95∘C followed by a
−1∘C/minute ramp down to 23∘C. To create ssRNA targets, short targets (Trunc2,
3, 4) were synthesized as top and bottom strand oligos containing the T7 promoter.
For long ssRNA targets (E1, E2, S and L CRISPR Arrays), DNA primers (Table S1)
with a T7 handle on the forward primer were ordered and the DNA fragment was
amplified using PCR. T7 DNA constructs for RNA generation without body labeling
were incubated with T7 polymerase overnight (10-14 hr) at 30∘C using the HiScribe
T7 Quick High Yield RNA Synthesis kit (New England Biolabs). Body-labeled con-
structs were incubated with Cyanine 5-UTP (Perkin Elmer) and incubated with T7
polymerase overnight at 30∘C using the HiScribe T7 High Yield RNA Synthesis kit
(New England Biolabs). For a complete list of crRNAs and target ssRNAs used in
this study see Table S1. 5′ end labeling was accomplished using the 5′ oligonucleotide
kit (VectorLabs) and with a maleimide-IR800 probe (LI-COR Biosciences). 3′ end
labeling was performed using a 3′ oligonucleotide labeling kit (Roche) and Cyanine
5-ddUTP (Perkin Elmer). RNAs were purified using RNA Clean and Concentrator
columnsTM-5 (Zymo Research). Body-labeled dsRNA substrates were prepared by
T7 DNA fragments for the bottom and top RNA strand. After synthesis, 1.3-fold
excess of non-labeled bottom strand ssRNA was added and re-annealed to ensure the
top strand would be annealed to a bottom strand by incubating the mixture for 1
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min at 95∘C followed by a −1∘C/minute ramp down to 23∘C.
Nuclease Assay Nuclease assays were performed with equimolar amounts of end-
labeled or body-labeled ssRNA target, purified protein, and crRNA, for targeted
ssRNA cleavage. For CRISPR array cleavage, protein was supplied in a four times
molar excess of the CRISPR array. Reactions were incubated in nuclease assay buffer
(10 mM TrisHCl pH 7.5, 50 mM NaCl, 0.5 mM MgCl2, 20 U SUPERase Inhibitor
(ThermoFisher Scientific), 0.1% BSA). Reactions were allowed to proceed at 37∘C for
times specified in the figure legends. After incubation, samples were then quenched
with 0.8U of Proteinase K (New England Biolabs) for 15 min at 25∘C. The reactions
were mixed with equal parts of RNA loading dye (New England Biolabs) and dena-
tured at 95∘C for 5 min and then cooled on ice for 2 min. Samples were analyzed
by denaturing gel electrophoresis on 10% PAGE TBE-Urea (Invitrogen) run at 45∘C.
Gels were imaged using an Odyssey scanner (LI-COR Biosciences).
EMSA Assay For the Electrophoretic Mobility Shift Assay (EMSA), binding ex-
periments were performed with a series of half-log complex dilutions (crRNA and
BzCas13b) from 0.594 to 594 nM. Binding assays were performed in nuclease assay
buffer (without MgCl2) supplemented with 10 mM EDTA to prevent cutting, 5% glyc-
erol, and 5 mg/mL heparin in order to avoid non-specific interactions of the complex
with target RNA. Protein was supplied at two times the molar amount of crRNA.
Protein and crRNA were preincubated at 37∘C for 15 min, after which the 5′-labeled
target was added. Reactions were then incubated at 37∘C for 10 min and then re-
solved on 6% PAGE TBE gels (Invitrogen) at 4∘C (using 0.5X TBE buffer). Gels
were imaged using an Odyssey scanner (LI-COR Biosciences). Gel shift of the RNA
targets was quantified from an EMSA gel using ImageJ (Wayne Rasband, NIH) and
plotted in GraphPad Prism version 7 (GraphPad Software, La Jolla California USA).
Line regression was performed in Prism 7 using nonlinear fit with one-site binding
83
hyperbola. 𝐾𝐷 values are calculated by GraphPad Prism based on regression analysis
of data (Table S7).
PbCas13b Protein Purification PbCas13b (Prevotella buccae) was cloned into
the same pET based vector and purified using a similar protocol as BzCas13b with
the following differences: cells were grown at 21∘C for 18 hr. Frozen cell paste was
resuspended into 500 mM NaCl, 50 mM HEPES 7.5 and 2 mM DTT prior to breaking
cells in the microfluidizer. The Superdex 200 column was run in 500 mM NaCl, 10
mM HEPES 7.0, and 2 mM DTT.
MS2 Phage Drop Plaque Assay Individual spacers for bacteriophage MS2 inter-
ference were ordered as complementary oligonucleotides containing overhangs allowing
for directional cloning in between two direct repeat sequences in vectors containing
cas13b (Table S2 and Table S6). 10 uM of each complementary oligo were annealed
in 10X PNK Buffer (NEB), supplemented with 10 mM ATP and 5 units of T4PNK
(NEB). Oligos were incubated at 37∘C for 30 min., followed by heating to 95∘C for
5 min. and then annealed by cooling to 4∘C. Annealed oligos were then diluted
1:100 and incubated with 25 ng of Eco31I digested cas13b vector in the presence of
Rapid Ligation Buffer and T7 DNA ligase (Enzymatics). Individual plasmids were
prepared using the QIAprep Spin Miniprep Kit (QIAGEN), sequence confirmed and
then transformed into C3000 (ATCC 15597) cells made competent using the Mix
& Go E. coli Transformation Kit (Zymo). In the case of experiments using csx27
or csx28, C3000 cells harboring csx plasmids were made competent and then trans-
formed with cas13b direct repeat-spacer-direct repeat plasmids. Following transfor-
mation, individual clones were picked and grown overnight at 37∘C in LB containing
the appropriate antibiotics. The following morning, cultures were diluted 1:100 and
grown to an OD600 of 2.0 by shaking at 37∘C with 5% CO2 at 250 rpm, then mixed
with 4mL of antibiotic containing Top Agar (10 g/L tryptone, 5 g/L yeast extract, 10
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g/L sodium chloride, 5 g/L agar) and poured on to LB-antibiotic base plates. 10-fold
serial-dilutions of MS2 phage (ATCC 15597-B1) were made in LB and then spotted
onto hardened top agar with a multi-channel pipette. Plaque formation was assessed
after overnight incubation of the spotted plates at 37 C. For assessing interference
levels in Figures 3-8E and 3-11D, samples were blinded using a key and the lowest
dilution of phage at which plaque formation occurred was compared to a pACYC
condition by eye, where the lowest dilution of MS2 that formed plaques on pACYC
was set to 1. The lowest dilution of phage used for Figure 3-8E was 1.05*108 pfu.
DNA Interference Assay A 34 nt target sequence consisting of a 30 nt proto-
spacer and a permissive PFS (5′-G, 3′-AAA) was cloned into pUC19 in two locations
(Table S2 and Table S6). For the transcribed target, the target sequence was cloned
into the coding strand of the bla gene, in frame immediately after the start codon,
with the G of the start codon serving as the 5′ PFS. For the non-transcribed target
the identical target sequence (protospacer and PFS) were cloned into the AatII site of
pUC19, so that the protospacer appears on the non-transcribed strand with respect
to the pBla and pLac promoters. To determine interference, 25 ng of the ampicillin
resistant target plasmid and 25 ng of the chloramphenicol resistant bzcas13b or empty
vector (pACYC) were added to 5 uL of NovaBlue GigaSingle cells (Novagen). The
cells were incubated for 30 min on ice, heatshocked for 30 s at 42∘C and incubated on
ice for 2 min. Then, 95 uL of SOC was added to cells and they were incubated with
shaking at 37∘C for 90 min, before plating the entire outgrowth (100 uL) on plates
containing both chloramphenicol and ampicillin.
RFP-Tagged Protein Fluorescent Imaging One Shot Stbl3 Chemically Com-
petent E. coli were transformed with plasmids containing RFP (negative control) or
RFP fused to the N- or C- terminus of Csx27 of B. zoohelcum or Csx28 of P. buccae
(Table S2). Clones were cultured up in 5 mL of antibiotic LB overnight, then spun
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down at 5000 g and resuspended in PBS with 1% methanol-free formaldehyde. After
30 min fixation, cells were washed once with PBS and then diluted 1:2 in PBS. 5uL
of sample was pipetted onto a silane-coated slide, which was covered with a coverslip.
Fluorescent imaging was performed in a 63x objective microscope with oil immersion.
3.9.3 Quantification and Statistical Analysis
MS2 Interference Assay-HEPN Mutants Three bioreplicates of the MS2 in-
terference assay were performed for the fold resistance quantification in Figures 3-8E
and 3-11D. For assessing interference levels in Figures 3-8E and 3-11D, samples were
blinded using a key and the highest dilution of phage at which plaque formation oc-
curred was compared to a vector only condition by eye, where the highest dilution of
MS2 that formed plaques on pACYC was set to 1. The error bars are the standard
deviation of the fold-resistance for each condition.
DNA Interference Assay Three bioreplicates of the DNA interference assay were
performed for the colony forming unit quantification. The mean values were taken
from the mean of number of colony forming units from a standard colony forming
unit count, and the standard deviation values accordingly from the same standard
count.
E. coli Essential Gene Screen Spacer depletions from the screen were calculated
as the read abundance of a spacer in the empty vector condition divided by read
abundance in each gene plasmid condition. Mean depletions over three bioreplicates
were calculated. We imposed a two-step quality-control filter on the data: a maximum
coefficient of variation of 0.2 for depletion over three bioreplicates, and a minimum
spacer read abundance of 1/3𝑁 in each bioreplicate, where 𝑁 = 55,700. This reduced
the number of guides represented from N to approximately 30,000-40,000.
For secondary structure analysis, we utilized the RNA accessibility model from
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Vienna RNAplfold (Bernhart et al., 2006). To apply this model to our data, we
separated spacers from our E. coli essential gene screen into training/testing cohorts
of five or more, each represented by a unique permissible PFS and gene and containing
at least one spacer in the top 2% of depleted spacers from the screen (to enhance
predictive signal). We then randomly divided these cohorts into a training set (80%)
and a testing set (20%), with the size of a testing set ranging from approximately 𝑛 =
40 to 𝑛 = 60, depending on the screen. For optimizing a secondary structure-mediated
model of efficient spacer design we selected as objective functions top 1 or top 3
accuracy, the percent of cohorts for which the top spacer is accurately predicted or falls
in the top 3 depleted spacers in a cohort, respectively. We gauged the performance
of this RNAplfold model relative to 106 Monte Carlo simulations performed on the
testing dataset and found empirical 𝑃 -values of less than 1e-2 for top 1 accuracy, and
less than 1e-5 for top 3 accuracy. Similar predictive power applied to pbcas13b with
pbcsx28, as well as to pbcas13b alone.
𝐾𝐷 Calculations Gel shift of the RNA targets was quantified from an EMSA
gel using ImageJ (Wayne Rasband, NIH) and plotted in GraphPad Prism version
7 (GraphPad Software, La Jolla California USA). Line regression was performed in
Prism 7 using nonlinear fit with one-site binding hyperbola. 𝐾𝐷 values are calculated
by GraphPad Prism based on analysis of regression data (Table S7).
3.9.4 Data and Software Availability
Data Resources Data have been deposited in the following resources:
Next-Generation Sequencing for E. coli essential gene screen, kanamycin vali-
dation screen: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA358111
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Chapter 4
Conclusion
4.1 Thesis Summary and Impact
The discovery and characterization of the class 2 CRISPR-Cas system Cas13b ad-
vanced the CRISPR field in two ways. First, it demonstrated that functional CRISPR
systems could exist without the adaptive machinery of Cas1 and Cas2 at their loci.
Second, it found that one particular class 2 RNA-targeting system possessed a nat-
ural “on/off” switch. These two properties are captured in the Graphical Abstract
from Smargon et al. (2017) (Figure 4-1). Although my research was predicated on
the notion that certain functional class 2 CRISPR systems might lack the canoni-
cal adaptive machinery, nevertheless the result is still surprising. If the systems are
functional yet cannot adapt, how did natural selection permit them to remain in the
efficient genomes of bacteria? Csx27 and Csx28 may hold the answer. It is perhaps
even more surprising that these auxiliary CRISPR proteins are nearly always present
at type VI-B loci. Undoubtedly there is more to the story.
Cas13b differs from the previously described Cas13a in several important re-
spects. For one, with the exception of the HEPN domains, the two effector proteins
have homologously distinct architectures (Shmakov et al., 2017). Next, while Cas13a
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Figure 4-1: Summary of Cas13b and Type VI-B System. Figure is Graphical
Abstract from Smargon et al. (2017).
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possesses a 5′ direct repeat, Cas13b possesses a 3′ direct repeat, with a short and long
variant in certain bacterial strains. As far as I understand, there is no precedent for
this native dual repeat functionality in the CRISPR field. The longer direct repeats
likely originated from an anomaly in adaptation, when a spacer integrated into the
center of a direct repeat. The ability of the longer direct repeat variant to then incor-
porate new spacers may provide clues as to the unique adaptive mechanism of VI-B
systems.
Finally, the 3′ protospacer-flanking sequence of Cas13a can be contrasted with
the double-sided protospacer-flanking sequence of Cas13b, whose additional sequence
requirements may make it more specific to RNA targeting. While certain class 1
CRISPR systems possess double-sided PFS variants, this finding is novel to class 2
CRISPR research. The additional finding that an adenosine residue must be located
in one of two positions in the 3′ PFS suggests a certain versatility in how Cas13b
interacts with target RNA on the basepair level. Solving the 3-dimensional structure
of Cas13b should conclusively resolve this phenomenon.
The E. coli essential gene screen developed in the Cas13b study further revealed
secondary structure requirements for RNA targeting. Unlike previously developed
assays, the screen generalized to tens of thousands of unique spacer and protospacer
sequences, and can be completed overnight after cloning. Surprisingly, the screen
proved to be extremely robust and reproducible, with 60–80% of spacer depletions
possessing a coefficient of variation of less than 0.2 and a minimum abundance of
1/3𝑁 . Further implementations of the screen may prove useful in unbiased nucleic
acid targeting assays of other CRISPR systems.
The greatest impact of the Cas13b study lies ahead. In the coming years, RNA
targeting will be transformed by Cas13 just as DNA targeting was transformed by
Cas9. As was discussed in Chapter 1, a number of proposed applications have yet to
be realized–and undoubtedly many more remain to be hypothesized.
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4.2 Future Research Directions
In the aftermath of the Cas13b study, several future research directions could be
pursued. With the exponential growth in the number of deposited microbial genomes,
a natural direction would be to continue searching for novel functional class 2 CRISPR
systems through established computational and sequencing approaches. Aside from
biocomputational work, many such proposed systems are waiting to be characterized
experimentally.
In addition to searching for new systems, there are a few unanswered scientific
questions about the CRISPR-Cas13b (VI-B) system. First, how do the VI-B CRISPR
arrays adapt, if at all, in the absence of Cas1 and Cas2? One possibility is that they do
not adapt, and formed around existing orphan CRISPR arrays. A second possibility
is that VI-B systems lost their ability to adapt at some point in evolution. The
seemingly prolific adaptation (abundance of spacers) of their CRISPR arrays argues
against each of these possibilities, unless there is a strong selective pressure to preserve
existing spacers. A third possibility is that VI-B systems adapt in trans, i.e., Cas1 and
Cas2 are co-opted from other CRISPR systems in the genome. It is widely believed,
however, that Cas1 and Cas2 co-evolve within a system to recognize a specific direct
repeat. The diversity of other CRISPR systems present in VI-B genomes, as well as
the robust conservation of the VI-B direct repeat, argue against this possibility. A
fourth and final possibility is that VI-B systems adapt autonomously, without Cas1
or Cas2. If accurate, this would shatter the prevailing doctrine in the CRISPR field.
Of the four possibilities, the second and third seem most probable, but the fourth
tantalizes the highest experimental reward.
As a second follow-up research question, what are the mechanisms of the reg-
ulatory co-factors Csx27 and Csx28? Curiously, the downregulating Csx27 is often
upstream of Cas13b, whereas the upregulating Csx28 is invariably downstream of
Cas13b. Could these relative positions speak to some transcriptional feedback at
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play? As far as the mechanism of interaction, do Csx27 and Csx28 interact with
the Cas13b protein, mRNA encoding for Cas13b, or the CRISPR array itself? The
predicted 𝛼-helices on both accessory proteins argue for binding with Cas13b. In
the case of Csx27, there is precedent in the CRISPR field for 𝛼-helix-containing
‘anti-CRISPRs’ of Cas9 to inhibit DNA binding competitively (Pawluk et al., 2016).
Similarly, Csx27 may competitively inhibit RNA binding to Cas13b. But what of the
‘pro-CRISPR’ Csx28? Does this agonist enhance RNA binding or RNA degradation?
The presence of a putative HEPN domain in Csx28 hints at the latter.
As a third follow-up research question, what is the function of Cas13-mediated
RNA degradation in bacteria? Does it truly protect against foreign invaders, or is
it a form of programmed cell death via the collateral effect? While these questions
were first posed when Cas13a was characterized, the differential regulation of Cas13b
affords more nuanced possibilities in exploring their answers experimentally.
Beyond scientific follow-up research, the Cas13b study paves the road for future
RNA-targeting tool development. Cas13b has already been engineered to edit RNA
when fused to the double-stranded RNA-specific adenosine deaminase ADAR (Cox
et al., 2017). In that study, several Cas13b orthologs were found to exhibit greater
RNA interference in human cells than all other Cas13a/c orthologs tested (Figure 4-
2A,B). One such ortholog, PspCas13b, interfered with RNA consistently more highly
than the human cell-optimal Cas13a, LwaCas13a, when tiled along two transcripts
(Figure 4-2C,D). In addition, PspCas13b had fewer detectable off-target sites, which
may be attributable to its more constrained protospacer-flanking sequence (Figure 4-
2E-G). The fact that there are numerous copies of a particular RNA molecule in a
cell may explain the superior performance of PspCas13b in both RNA interference
and targeting specificity.
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Figure 4-2: Characterization of a highly active Cas13b ortholog for RNA
knockdown. (A) Schematic of stereotypical Cas13 loci and corresponding crRNA
structure. (B) Evaluation of 19 Cas13a, 15 Cas13b, and 7 Cas13c orthologs for lu-
ciferase knockdown using two different guides. Orthologs with efficient knockdown
using both guides are labeled with their host organism name. Values are normalized
to a non-targeting guide with designed against the E. coli LacZ transcript, with no
homology to the human transcriptome. (C) PspCas13b and LwaCas13 a knockdown
activity (as measured by luciferase activity) using tiling guides against Gluc. Values
represent mean +/− SEM Non-targeting guide is the same as in (B). (D) PspCas13b
and LwaCas13a knockdown activity (as measured by luciferase activity) using tiling
guides against Cluc. Values represent mean +/− SEM Non-targeting guide is the
same as in (B). (E) Expression levels in log2 (transcripts per million (TPM+1)) val-
ues of all genes detected in RNA-seq libraries of non-targeting control (x-axis) com-
pared to Gluc-targeting condition (y-axis) for LwaCas13a (red) and shRNA (black).
Shown is the mean of three biological replicates. The Gluc transcript data point is
labeled. Non-targeting guide is the same as in (B). (F) Expression levels in log2
(transcripts per million (TPM+1)) values of all genes detected in RNA-seq libraries
of non-targeting control (x-axis) compared to Gluc-targeting condition (y-axis) for
PspCas13b (blue) and shRNA (black). Shown is the mean of three biological repli-
cates. The Gluc transcript data point is labeled. Non-targeting guide is the same as
in (B). (G) Number of significant off-targets from Gluc knockdown for LwaCas13a,
PspCas13b, and shRNA from the transcriptome wide analysis in (E) and (F). Figure
and figure legend are from Cox et al. (2017).
The structure of Cas13a has been solved (Liu et al., 2017; Knott et al., 2017),
and it is only a matter of time before the same is true for Cas13b. With this structure
in hand, rationally based design of Cas13b RNA-targeting tools will be achievable.
Engineered Cas13b may be used to optimize nucleic acid detection (Gootenberg et
al., 2017) or design more versatile RNA mammalian synthetic biology circuits (Isaacs
et al., 2006; Chappell et al., 2015; Wroblewska et al., 2015; McKeague et al., 2016).
Whichever direction scientists and engineers decide to take, Cas13b will likely play
an important role in the future of RNA research.
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Appendix A
Molecular Cell Paper Tables
A.1 Supplementary Tables
To download supplementary tables, visit http://www.cell.com/molecular-cell/
fulltext/S1097-2765(16)30866-8.
Table S1. All crRNAs, nucleic acid targets, and primers used in biochemical
experiments. Related to Figures 2-8, 3-4 and 3-8. See separate Excel file.
Table S2. All Cas13b plasmids used in this study. Related to Figures 3-1, 3-8,
and 3-11. See separate Excel file.
Table S3. E. coli essential genes represented in E. coli essential gene screen
library of spacers. Related to Figures 3-1, 3-9, and 3-11. See separate Excel file.
Table S4. Spacers from E. coli essential gene screen. Related to Figures 3-
1, 3-9, and 3-11. See separate Excel file.
Table S5. Spacers from kanamycin validation screen. Related to Figure 3-1.
See separate Excel file.
Table S6. Spacers targeting MS2 and pBLA plasmids. Related to Figures 3-8
and 3-11. See separate Excel file.
Table S7. EMSA raw data. Related to Figure 3-8. See separate Excel file.
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A.2 Key Resources Table
REAGENT or RE-
SOURCE
SOURCE IDENTIFIER
Chemicals, Peptides, and Recombinant Proteins
BzCas13b This study Table S2
BzCas13b mutants (D1, D2,
Q)
This study Table S2
PbCas13b This study Table S2
SUPERase RNase Inhibitor Thermo Fisher Sci-
entific
AM2696
TURBO DNase Life Technologies AM2238
SUMO protease Thermo Fisher Sci-
entific
12588018
Critical Commercial Assays
MiSeq Reagent Kit v3 (150 cy-
cles)
Illumina MS-102-3001
NextSeq 500/550 High Output
v2 kit (150 cycles)
Illumina FC-404-2002
HiScribe T7 High Yield RNA
Synthesis kit
New England Bio-
labs
E2040S
HiScribe T7 Quick High Yield
RNA Synthesis kit
New England Bio-
labs
E2050S
5′ oligonucleotide kit VectorLabs MB-9001
98
Deposited Data
EMSA raw data This study Table S7
Next-generation sequencing
for bacterial RNA sequencing,
E. coli essential gene screen,
kanamycin validation screen
This study https://www.ncbi.nlm.
nih.gov/bioproject/
PRJNA358111
Experimental Models: Cell Lines
Experimental Models: Organisms/Strains
B. zoohelcum ATCC 43767
E. coli ATCC 15597
E. coli bacteriophage MS2 ATCC 15597-B1
One Shot Stbl3 E. coli Thermo Fisher Sci-
entific
C737303
NEB 10-beta Competent E.
coli (High Efficiency)
New England Bio-
Labs
C3019H
MegaX DH10B T1R electro-
competent cells
Thermo Fisher Sci-
entific
C640003
One Shot BL21(DE3)pLysE
chemically competent E. coli
Invitrogen C656503
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Recombinant DNA
pMAX-GFP Lonza Not commercially available,
except as part of a nucle-
ofection kit: http://bio.
lonza.com/fileadmin/
groups/FAQs/public/
Technology_Flyer.pdf
6x His/Twin Strep SUMO, a
pET-based vector
Gift from Ilya
Finkelstein
N/A
Plasmids generated in this
study
This study Table S2
Sequenced Based Reagents
List of spacers for E. coli es-
sential gene screen
This study Table S4
List of spacers for kanamycin
validation screen
This study Table S5
List of spacers for MS2 inter-
ference and pBLA assays
This study Table S6
ssRNA targets This study Table S1
DNA primers This study Table S1
crRNAs This study Table S1
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Software and Algorithms
PILER-CR Edgar, 2007 http://drive5.com/
pilercr/
BLASTP Camacho et al.,
2009
https://blast.ncbi.nlm.
nih.gov/Blast.cgi?PAGE=
Proteins
HHpred Remmert et al.,
2011
https://toolkit.
tuebingen.mpg.de/
hhpredl
BLOSUM62 Henikoff and
Henikoff, 1992
Vienna RNAfold Anantharaman et
al., 2013; Lorenz et
al., 2011
http://rna.tbi.univie.
ac.at/
CRISPRTarget Biswas et al., 2013 http://bioanalysis.
otago.ac.nz/
CRISPRTarget/crispr_
analysis.html
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Software and Algorithms (cont.)
Burrows-Wheeler Aligner Li and Durbin,
2009
http://bio-bwa.
sourceforge.net
The Galaxy Project Center for Com-
parative Genomics
and Bioinformatics
at Penn State, and
Department of Bi-
ology and at Johns
Hopkins University
https://usegalaxy.org
Vienna RNAplfold Bernhart et al.,
2006
http://rna.tbi.univie.
ac.at/
ImageJ Wayne Rasband,
NIH
https://imagej.nih.gov/
ij/
GraphPad Prism version 7 GraphPad Soft-
ware, La Jolla,
California USA
https://www.
graphpad.com/
scientific-software/
prism/
MATLAB MathWorks, Nat-
ick, Massachusetts,
United States
hhttps://www.mathworks.
com/products/matlab.
html
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Appendix B
Diversity and Evolution of Class 2
CRISPR-Cas Systems
This appendix is derived in part from the Nature Reviews Microbiology class 2
CRISPR diversity and evolution analysis article (Shamkov et al., 2017). Full citation
is as follows:
Shmakov, S., Smargon, A., Scott, D., Cox, D., Pyzocha, N., Yan, W., Abu-
dayyeh, O.O., Gootenberg, J.S., Makarova, K.S., Wolf, Y.I., Severinov, K., Zhang, F.
and Koonin, E.V. (2017). Diversity and evolution of class 2 CRISPR-Cas systems.
Nat. Rev. Microbiol. 15, 169−182.
Contributions: I contributed to the discovery pipeline and parts of the text
in this analysis article.
B.1 Abstract
Class 2 CRISPR-Cas systems are characterized by effector modules that consist of
a single multidomain protein such as Cas9 or Cpf1. We designed a computational
pipeline for the discovery of novel Class 2 variants and used it to identify six new
CRISPR-Cas subtypes. The diverse properties of these new systems provide potential
for the development of versatile tools for genome editing and regulation. We present
a comprehensive census of Class 2 types and Class 2 subtypes in complete and draft
bacterial and archaeal genomes, outline evolutionary scenarios for the independent
103
origin of different Class 2 CRISPR-Cas systems from mobile genetic elements, and
propose an amended classification and nomenclature of CRISPR-Cas.
B.2 Introduction
CRISPR-Cas (clustered regularly interspersed palindromic repeats and CRISPR-
associated genes) systems provide adaptive immunity in archaea and bacteria
(Makarova et al., 2006; Barrangou et al., 2007; Barrangou, 2013; Marraffini, 2015;
Mohanraju et al., 2016). The structural features and mechanisms of CRISPR-Cas
are described in detail in many recent reviews (Barrangou, 2013; Marraffini, 2015;
Mohanraju et al., 2016; van der Oost et al., 2014). Briefly, the CRISPR-Cas response
consists of three stages. During the first stage, known as adaptation, the Cas1-Cas2
protein complex (which in some cases contains additional subunits) excises a segment
of the target DNA (known as the protospacer) and inserts it between the repeats at
the 5′ end of a CRISPR array, yielding a new spacer. In the expression and processing
stage—a CRISPR array, together with the spacers, is transcribed into a long tran-
script known as the pre-CRISPR (cr) RNA and processed by a distinct complex of
Cas proteins (which in some cases involves additional proteins and RNA molecules)
into mature, small crRNAs. Finally, during the interference stage, a complex of Cas
proteins (typically, a modified processing complex) employs the crRNA as a guide to
cleave the target DNA or RNA. Similarly to other defense mechanisms, CRISPR-Cas
systems have evolved in the context of an incessant arms race with mobile genetic
elements, resulting in extreme diversification of the Cas protein sequences and in the
architecture of the CRISPR-cas loci (Makarova et al., 2011a; Makarova et al., 2013;
Takeuchi et al., 2012; Bondy-Denomy and Davidson, 2014; Bondy-Denomy et al.,
2015; van Houte et al., 2016). Owing to this diversity and the lack of universal cas
genes, a comprehensive classification of the CRISPR-Cas systems cannot be generated
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as a single phylogenetic tree but requires a multipronged approach that combines the
identification of signature genes with phylogenetic trees and the analysis of sequence
similarity between partially conserved cas genes, as well as the comparison of the
loci organization (Makarova et al., 2011b; Makarova and Koonin, 2015). The latest
published CRISPR-Cas classification includes two classes that are subdivided into
five types and 16 subtypes (Makarova et al., 2015). Shortly after this classification a
sixth type and three additional subtypes were identified (Shmakov et al., 2015).
Class 1 CRISPR-Cas systems, with multisubunit effector complexes, are most
common in bacteria and in archaea (including in all hyperthermophiles), comprising
∼90% of all identified CRISPR-cas loci (Makarova et al., 2015). The remaining ∼10%
of CRISPR-Cas systems belong to Class 2 (which use a type II, V or VI effector
protein); these systems are found almost exclusively in bacteria and have not been
identified in hyperthermophiles (Makarova et al., 2015; Chylinski et al., 2014).
The CRISPR-Cas systems are characterized by pronounced functional and evo-
lutionary modularity (Makarova et al., 2013). The adaptation module responsible for
spacer acquisition shows limited variation among the diverse CRISPR-Cas systems
(Makarova et al., 2015). By contrast, the CRISPR-Cas effector module that mediates
the maturation of crRNAs, as well as target recognition and cleavage, is more versatile
in gene composition and locus architecture; this led to the two classes of CRISPR-Cas
systems being defined based on the different organization of their effector modules
(Makarova et al., 2013). The effector complexes of Class 1 systems consist of 4 to
7 Cas protein subunits in an uneven stoichiometry, as exemplified by the CRISPR-
associated complex for antiviral defense (Cascade) of the Type I systems (Brouns
et al., 2008; Jore et al., 2011; Beloglazova et al., 2015; Jackson et al., 2014) and the
Csm-Cmr complexes of the Type III systems (Rouillon et al., 2013; Staals et al., 2014;
Osawa et al., 2015; Taylor et al., 2015). In contrast, the signature feature of Class
2 systems is an effector module that consists of a single, multi-domain protein. The
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relatively simple architecture of its effector complex has made Class 2 CRISPR-Cas
systems an attractive choice for use in the new generation of genome-editing tools
(Jinek et al., 2012; Cong et al., 2013; Mali et al., 2013; Gasiunas et al., 2012).
Prior to the analysis reported here, five (predicted) Class 2 effectors had been
described — Cas9, Cpf1, C2c1, C2c2 and C2c3 — the most common and best studied
of which is the type II effector, Cas9. Cas9 is a crRNA-dependent endonuclease that
contains two unrelated nuclease domains, RuvC and HNH, which are responsible for
the cleavage of the displaced (non-target) and target DNA strands, respectively, in
the crRNA-target DNA complex (Jinek et al., 2012; Gasiunas et al., 2012; Nishimasu
et al., 2014; Nishimasu et al., 2015; Sternberg et al., 2015; Sapranauskas et al., 2011).
The Type II CRISPR-Cas loci also encode a trans-acting crRNA (tracrRNA) that
might have evolved from the corresponding CRISPR and that is essential for pre-
crRNA processing and target recognition in Type II systems (Jinek et al., 2012;
Deltcheva et al., 2011; Chylinski et al., 2013; Briner et al., 2014). The protein
sequence of Cpf1, the prototype type V effector, contains only one readily detectable
nuclease domain, RuvC (Makarova et al., 2015; Schunder et al., 2013; Zetsche et
al., 2015). However, structures of Cpf1 complexed with the crRNA, or with both
crRNA and target DNA, reveal a second nuclease domain with a unique fold that
is functionally analogous to the HNH domain of Cas9 (Dong et al., 2016; Yamano
et al., 2016). An important difference between Cpf1 and Cas9 is that Cpf1 is a
single RNA-guided nuclease that does not require a tracrRNA. Furthermore, the
Cpf1 protein itself is responsible for pre-crRNA processing, although the nature of
its RNAse activity is not characterized (Fonfara et al.; 2016). Cpf1 also differs from
Cas9 in its cleavage pattern and in its protospacer-adjacent motif (PAM), which
determines which targets are cleaved (Zetsche et al., 2015). These differences suggest
that the discovery of novel Class 2 effectors could enhance the application of CRISPR
systems to genome engineering. Furthermore, the discovery of two, distantly related
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Class 2 effector proteins, Cas9 and Cpf1, suggests that other, distinct variants of
such systems could exist. Prompted by these findings, we developed a computational
pipeline to systematically identify novel Class 2 CRISPR-Cas loci in genomic and
metagenomic sequences. Using Cas1, the most conserved Cas protein, as a seed, we
identified three previously unknown Class 2 subtypes, two of which contained effectors
distantly related to Cpf1 and were included as additional subtypes in type V; the third
novel Class 2 subtype became the new type VI subtype (Shmakov et al., 2015). The
expression and ability to cause interference of two of these proteins, denoted C2c1
and C2c2, has been experimentally demonstrated (Shmakov et al., 2015; Abudayyeh
et al., 2016).
In this Analysis article, we expand on our previous findings (Shmakov et al.,
2015; Abudayyeh et al., 2016) and describe further analysis that we believe provides a
comprehensive census of Class 2 effectors in sequenced bacterial and archaeal genomes.
This new analysis stems from the observation that many known CRISPR-Cas systems
are non-autonomous; that is, they depend on Cas1 and Cas2 proteins that are supplied
by other CRISPR-Cas loci in the same genome and, as such, their loci lack cas1
(Makarova et al., 2015) and will not have been detected in our previous analyses
(Makarova et al., 2015; Shmakov et al., 2015). We extended the search for novel
Class 2 systems by using the CRISPR array itself as the seed. As a result, we identify
novel, putative Class 2 effectors that were missed in the previous analyses (Makarova
et al., 2015; Shmakov et al., 2015) and which belong to at least three new CRISPR-Cas
subtypes. We further discuss the evolutionary implications of our findings, including
evidence of a crucial role for mobile genetic elements in the independent origin of
different types and subtypes of Class 2 systems.
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B.3 Comparative Genomics and Evolution
B.3.1 Subtypes V-A, V-B and V-C Identified with Cas1 Seed:
Large Multidomain Effectors
The distinctive feature of type II and type V CRISPR-Cas sequences is the presence,
in the multidomain effector proteins, of a RuvC-like nuclease domain. In the type
II effector Cas9, the RuvC-like domain contains an inserted HNH nuclease domain
(Figures B-1 and B-2). Other than the RuvC-like domain, the effector proteins of the
three type V subtypes do not share any detectable sequence similarity to each other or
to Cas9. However, the only available crystal structures of Class 2 effectors, specifically
those of Cas9 and Cpf1, reveals that they have a common structural framework (see
above) (Dong et al., 2016; Yamano et al., 2016). The structures of the putative
large type V effectors that were discovered using the cas1 seed, namely those of the
subtypes V-B and V-C, are unsolved, but the subtype V-B effector C2c1 was shown
to have robust interference activity (Shmakov et al., 2015). All the class V effectors
identified at this stage share a similar, large size (typically, 1000 to 1,300 amino acid
residues) and a single common domain, the RuvC-like endonuclease, although the
sequence similarity between the effector proteins of different subtypes is extremely
low. It is likely that all type V effectors adopt similar bilobed structures that hold
together the crRNA and the target DNA, although the effector proteins of different
subtypes do not appear to be directly related.
The search for homologs of the type II and type V effectors showed that the
RuvC-like nuclease domains are related to TnpB proteins, an extremely abundant
but poorly characterized family of nucleases that is encoded by many autonomous
(that is, those that encode an active transposase, denoted TnpA, and mediate their
own transposition) and even more numerous non-autonomous (that is, those that
consist solely of the tnpB gene and rely on transposases from other elements for their
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transposition) bacterial and archaeal transposons (Figure B-3a) (Pasternak et al.,
2013; Bao et al., 2013; Kapitonov et al., 2015). In addition to the RuvC-like nuclease
domain, TnpB proteins contain a predicted long, positively charged, long 𝛼-helix
that appears to be the counterpart to the bridge helix, a common feature of Cas9 and
Cpf1 (Figure B-2). Thus, similar to the Class 2 effectors, the TnpB proteins can be
predicted to bind RNA. Moreover, it has been reported that a TnpB protein from the
haloarchaeon Halobacterium salinarium binds short overlapping sense transcripts of
its own gene (Gomes-Filho et al., 2015). Biochemical and biological characterization
of TnpB should shed light on the evolution of the functions of Class 2 CRISPR-Cas
effectors.
The closest relatives and possible ancestors of Cas9 have been identified on the
basis of readily detectable sequence similarity and on the presence of the HNH insert
in the RuvC-like nuclease domain of a distinct family of TnpB proteins that is denoted
IscB (Insertion Sequences Cas9-like protein B) (Chylinski et al., 2014; Kapitonov et
al., 2015). It is difficult to confidently trace a direct connection between type V
effector proteins and a particular group of TnpB proteins because type V effector
proteins show less similarity with TnpB proteins than Cas9 shows to IscB proteins
Nevertheless, the effectors of the three subtypes of type V are similar to different
TnpB families, suggesting independent origins of the effectors of different type V
subtypes from the pool of tnpB genes (Shmakov et al., 2015).
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Figure B-1: The updated classification scheme for class 2 CRISPR-Cas
systems. The class 1 systems are collapsed; all other systems shown are class 2
systems. New class 2 systems that were discovered using the computational pipeline
in this study are indicated with blue circles for those that were described previously
(Shmakov et al., 2015) and with red circles for those that are presented here for the
first time. For each class 2 system subtype, as well as for the five distinct variants
of the provisional V-uncharacterized (V-U) subtype, the locus organization and the
domain architecture of the effector and accessory proteins are schematically shown.
RuvC-I, RuvC-II and RuvC-III are the three distinct motifs that contribute to the
nuclease catalytic center; numerals in the figure correspond to the respective RuvC
motif. The portions of Cas9 proteins that roughly correspond to the recognition lobe
and the protospacer-adjacent motif (PAM)-interacting domain are shown by maroon
and pink shapes, respectively. The proposed new systematic gene names are shown
in bold type in red boxes. Provisional gene name for effector protein candidates are
shown below the respective shapes as follows: C2c1−10, class 2 candidate proteins
1-10; for subtype V-A, the previously introduced vernacular cpf1 is indicated. For
subtype VI-A, cas1 and cas2 are shown with dashed contours to indicate that only
some of these loci include the adaptation module. For the V-U5 variant, the inacti-
vation of the RuvC-like nuclease domain is indicated by a cross. The specific strains
of bacteria in which these systems were identified and locus tags for the respective
protein-coding genes are also indicated. The abbreviation TM indicates a predicted
transmembrane helix. The predicted type of target, namely DNA or RNA, is indi-
cated for each subtype. A question mark next to the target indicates that the activity
is only predicted and has not been demonstrated experimentally. The target is not
indicated for the type V-U systems because their RNA-guided interference capacity is
questionable, which is additionally emphasized by shading. tracrRNA, trans-acting
CRISPR RNA.
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Figure B-2: The domain architecture of class 2 CRISPR effector proteins.
For the type II and subtype V-A effectors, the crystal structures (indicated here by
their RCSB Protein Data Bank (PDB) accession numbers (5CZZ and 5B43, respec-
tively)) are available and the corresponding domain architectures are shown in detail.
For the remainder of the proteins, the grey areas indicate structurally and functionally
uncharacterized portions. RuvC-I, RuvC-II and RuvC-III, as well as higher eukary-
otes and prokaryotes nucleotide-binding I (HEPN I) and HEPN II, denote the cat-
alytic motifs of the respective nuclease domains of the CRISPR effectors. The bridge
helix corresponds to an arginine-rich region that follows the RuvC-I motif. Other
domains shown in the figure are denoted as follows: PAM interacting, protospacer-
adjacent motif (PAM)-interacting domain; HNH, HNH family endonuclease domain,
zinc finger domain with a CXXC..CXXC motif (dots represent the variable distance
between the two pairs of cysteines); HTH, putative DNA-binding helix-turn-helix do-
main; NUC, nuclease domain. The proteins and domains are shown approximately to
scale. For each protein, the corresponding number of amino acids is indicated, and a
ruler is shown on top of the figure to guide the eye. For the functionally characterized
full-length effectors, the proposed new nomenclature (Cas12 and Cas13) is indicated,
whereas for the uncharacterized putative effectors of type V-uncharacterized (V-U),
only the provisional names are indicated. When, and if, functional evidence of a
bona fide CRISPR response is reported for these effectors, they should be referred
to as Cas12 proteins with the corresponding specifying letters. The putative V-U1,
V-U2 and V-U5 effectors are larger than the typical TnpB proteins, whereas the V-U3
and V-U4 effectors are in the characteristic size range of TnpB. The asterisk at C2c5
indicates that this putative effector protein contains replacements of the catalytic
residues of the RuvC-like nuclease domain and lacks the zinc finger.
B.3.2 Subtype V-U Identified with CRISPR Seed: Small Pu-
tative Effectors
The search for CRISPR-cas loci lacking the adaptation module (that is, loci that were
identified with a CRISPR seed but not with a cas1 seed) yielded several additional
variants of putative type V systems (Figures B-1 and B-2) that might help explain
how CRISPR-Cas effectors evolved from TnpB. The putative effector proteins of these
loci that we have provisionally assigned to subtype V-U (where the ‘U’ stands for
‘uncharacterized’; see below) share two features that distinguish them from the type II
and type V effectors found at CRISPR-cas loci that contain Cas1 (Figure B-2). First,
these proteins are much smaller than Class 2 effectors that contain Cas1, comprising
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between ∼500 amino acids (only slightly larger than the typical size of TnpB) and
∼700 amino acids (between the size of TnpB and the typical size of the bona fide
Class 2 effectors). Second, these putative effectors show a higher level of similarity
to TnpB proteins than the larger type I and type V effectors. In particular, three
groups of TnpB homologues included here in subtype V-U (denoted V-U1,2,5) showed
evolutionary stability in terms of sequence conservation, consistent association with
CRISPR arrays, and presence in distinct groups of bacteria (Figures B-1 and B-2;
see below). A more detailed examination showed that, within each of these groups,
in closely related bacterial genomes the respective loci were genuinely orthologous, as
indicated by the gene synteny conservation.
In view of the identification of these smaller, CRISPR-associated TnpB ho-
mologs, we ran the pipeline with the requirement for the minimal length of the pro-
tein adjacent to the CRISPR-array lifted and examined the results for the presence
of additional TnpB homologs. Numerous CRISPR-associated TnpB homologs were
detected in the size range typical of the transposon-encoded TnpB, that is, ∼400
amino acids. Most of these loci were not evolutionarily conserved and were thus of
questionable functional relevance. However, we additionally detected two distinct
groups of such smaller, CRISPR-associated TnpBs (V-U3 and V-U4) with charac-
teristics similar to those of the three subtype V-U groups with intermediately sized
CRISPR-associated TnpBs (Figures B-1 and B-2).
Notably, the genes for the putative effectors of subtype V-U showed signs of
purifying selection on protein sequences (as indicated by the low values of the non-
synonymous to synonymous nucleotide substitutions, dN/dS ), which was found to
be particularly strong for the V-U3 group. Taken together, these observations imply
that the respective TnpB homologs have CRISPR-dependent functions and, in our
view, justify designating the respective loci subtype V-U.
Whereas for the larger, bona fide type V effectors, low sequence conservation
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precluded reliable phylogenetic analysis, a robust tree could be constructed for the
smaller CRISPR-associated homologs together with the typical, transposon-encoded
TnpB. The topology of this tree indicated that 4 of the 5 distinct variants of subtype
V-U (hereinafter referred to as V-U1−V-U5) originated from different TnpB families
(Figure B-3a), in agreement with the hypothesis on the independent evolution of dif-
ferent Class 2 subtype effectors from transposon-encoded nucleases. The fifth variant
(V-U5), which is found in a variety of Cyanobacteria, consists of diverged TnpB ho-
mologs with multiple mutations in the catalytic motifs of their RuvC-like domain and
was accordingly not included in the phylogeny here. Of the 5 stable variants, V-U1
is found in diverse bacteria whereas the remaining ones are largely limited in their
spread to particular bacterial taxa (Figure B-3a). We further extended this evolution-
ary analysis to all putative type V effectors by building a cluster dendrogram based
on the distances derived from profile to profile comparisons of the respective protein
sequences. The results suggest that the effectors of each of the identified subtypes,
as well as the 5 distinct variants within subtype V-U, originated independently from
different TnpB families.
The subtype V-U TnpB-like proteins are too small to adopt a bilobed structure
of sufficient size to accommodate the crRNA-target DNA complex, as the typical
Class 2 effectors do, and therefore are unlikely to function in that capacity with-
out additional partners. Furthermore, the subtype V-U loci lack any additional cas
genes (Figure B-1) which, together with the above structural considerations, calls for
caution in predicting that they harbour full-fledged CRISPR activity. Nevertheless,
the evolutionarily stable association of at least 5 distinct V-U variants with CRISPR
arrays implies that at least some of these proteins do perform CRISPR-dependent
biological functions. Such functions might involve a typical CRISPR response that
is aided by Cas proteins from other loci and/or by additional, non-Cas proteins. Re-
markably, the CRISPR arrays associated with group V-U3, which is mostly found in
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Bacilli and Clostridia, contain multiple spacers matching genomic sequences of bac-
teriophages that infect these bacteria. Furthermore, the sets of spacers within each
subtype V-U group were completely different, even between closely related bacterial
genomes, which implies active spacer turnover. The diversity of the spacers and the
presence of the phage-specific spacers in V-U3 imply that at least some subtype V-U
variants are functional CRISPR-Cas systems that are engaged in anti-phage adaptive
immunity. Many of the complete genomes containing V-U3 and V-U4 loci lack any
additional CRISPR-Cas systems, which makes it puzzling how these systems acquire
their spacers. Alternatively, some of the V-U systems might have distinct regulatory
roles that do not require the formation of a ternary complex with the crRNA and
the DNA target; indeed, several non-defense functions of CRISPR-Cas have been
described (Westra et al., 2014). This possibility is particularly plausible for the V-
U5 variant, which appears to encompass a catalytically inactive TnpB homologue
(Figure B-2, denoted C2c5). Furthermore, in genomes that contain the V-U2 and
V-U5 loci, along with other CRISPR-Cas systems, the CRISPR sequences associated
with the former loci are unique, suggesting that these type V-U systems have distinct
functions.
The signature of type VI systems is the presence of an effector protein contain-
ing two HEPN domains (Figures B-1 and B-2). The HEPN domains are common
in various defense systems, the experimentally characterized of which, such as the
toxins of numerous prokaryotic toxin-antitoxin systems or eukaryotic RNase L, all
possess RNase activity (Anantharaman et al., 2013; Makarova et al., 2014). There-
fore, the first putative type VI effector, denoted C2c2, was predicted to function as
an RNA-guided RNase (Shmakov et. al, 2015). Subsequently, this prediction was
experimentally validated, and the type VI effectors were shown to protect against
the RNA bacteriophage MS2 (Abudayyeh et al., 2016). In addition, a novel feature
of C2c2 is that, once primed with the cognate target RNA, the effector turns into
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a promiscuous RNase that has a toxic, growth-inhibitory effect on bacteria. These
findings demonstrate a coupling between adaptive immunity and programmed cell
death (or dormancy induction) that was previously predicted via comparative ge-
nomic analysis (Makarova et al., 2012) and mathematical modeling (Iranzo et al.,
2015). More recently, the C2c2 protein was shown to mediate not only interference
but also pre-crRNA processing (East-Seletsky et al., 2016). Since then, the tertiary
structure of C2c2 (Cas13a) has been determined, confirming that it possesses two
HEPN domains that interact to cleave target RNA and an additional catalytic site
that controls pre-crRNA cleavage (Liu et al., 2017).
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Figure B-3: Phylogenies of the type V and type VI-B effectors. A
maximum-likelihood phylogenetic tree of TnpB nucleases, including the putative type
V-uncharacterized (V-U) effectors that have a predicted active RuvC domain. The
major subtrees of transposon-encoded TnpB proteins are collapsed and indicated by
triangles; some of these large groups include tnpB genes that are adjacent to CRISPR
arrays, but these do not show evolutionary stability and thus cannot be identified as
effectors. The four distinct evolutionarily stable groups of CRISPR-associated TnpB
assigned to subtype V-U are shown by red triangles. Altogether, the tree includes
1,770 unique TnpB sequences, 403 of which are TnpB proteins that are encoded next
to TnpA (autonomous transposons); 168 of these tnpB genes are adjacent to CRISPR
arrays, and of these, 49 are assigned to four variants of subtype V-U (none of these
belongs to autonomous transposons). In the subtrees that include the subtype V-U
variants, bootstrap values (percentages) are shown for those subtrees that include the
distinct V-U variants. For each type V-U variant, the bacterial taxa that harbour
the majority of the respective loci are indicated. Dominant bacterial or archaeal lin-
eages, if there are any, are indicated in the triangles. b | Phylogenetic tree of the
subtype VI-B Cas13b effector proteins. The tree was constructed as in part a, and
the bootstrap values that are larger than 70% are indicated. The organization of
typical cas13b loci for selected representatives (specifically those that are shown in
bold) is schematically shown on the right. Variant 1 and variant 2 correspond to the
two major branches of the tree and differ with respect to the domain architectures
of the second smaller protein encoded in the locus; the domain architectures of these
putative accessory proteins are shown above (for variant 1) and below (for variant
2) the respective loci schematics. The CRISPR arrays are shown schematically in
brackets. TM indicates a predicted transmembrane domain, shown by blue boxes.
Higher eukaryotes and prokaryotes nucleotide-binding (HEPN) domains are shown as
maroon boxes. A, diverse archaea; B, diverse bacteria.
B.3.3 Subtypes VI-B and VI-C Identified with CRISPR Seed:
RNA-targeting CRISPR-Cas
The search for CRISPR-Cas loci using the CRISPR seed identified two additional
large putative effectors that contain two HEPN domains and which we assigned to
subtypes VI-B and VI-C, respectively (the C2c2-encoding loci accordingly became
subtype VI-A). This classification of the type VI systems into separate subtypes
is justified by the extremely low sequence similarity between the three groups of
effectors, which is practically limited to the catalytic motif of the HEPN domain, the
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different positions of the HEPN domains with the large protein sequences, and the
additional features of the locus architecture in the case of subtype VI-B (Figures B-1
and B-2). Specifically, the two distinct variants of subtype VI-B, VI-B1 and VI-B2,
both encode additional proteins that contain predicted transmembrane domains; VI-
B1 encodes one of these and VI-B2 contains four (Figure B-3b). Phylogenetic analysis
of the effector proteins suggests that the VI-B1 and VI-B2 variants diverged during
evolution in accordance with the distinct architectures of the associated predicted
membrane proteins (Figure B-3b). Furthermore, the single-transmembrane protein
of VI-B1 encompasses an additional HEPN domain, the third one in the Type VI
system (Figure B-3b). It was shown recently that the VI-B effector Cas13b has
collateral RNA catalytic activity, which is differentially regulated in the VI-B1 and
VI-B2 systems (Smargon et al., 2017).
Given that all of the putative type VI effectors discovered so far are similar
in size to the active Class 2 effectors of subtype VI-A (Anantharaman et al., 2013),
even those loci that lack cas1 are likely to be functional CRISPR-Cas systems that
rely on adaptation modules from other loci in the same genome. Moreover, given
that RNA viruses only represent a minor part of the prokaryotic virome (Koonin et
al., 2015), type VI systems might primarily elicit toxin activity in response to the
active transcription of foreign DNA. This mechanism might not be limited to type VI
given the presence of HEPN domains in poorly characterized Cas proteins in many
CRISPR-Cas systems; indeed, the RNase activity of the HEPN-containing Csm6 and
Csx1 proteins in type III systems has been demonstrated (Sheppard et al., 2016;
Niewoehner et al., 2016), whereas their functions in the CRISPR response remain to
be studied.
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B.4 Census of Class 2 CRISPR-Cas Loci
The design of our CRISPR-Cas discovery pipeline implies that the analysis described
in this article has identified nearly all variants of Class 2 systems that are present
in the currently available bacterial and archaeal genomes. Given that the current
databases include only a small fraction of the entire inferred microbial diversity of
the biosphere (Curtis et al., 2002; Curtis et al., 2006; Fraser et al., 2009; Quince et
al, 2008), the discovery of new CRISPR-Cas subtypes, or even of novel CRISPR-Cas
types, is likely. However, such novel variants are expected to be either extremely rare
or limited in their spread to specific groups of microbes that are at present poorly
sampled.
B.4.1 Comprehensive Census of Class 2 CRISPR-Cas Loci in
Bacteria and Archaea
Therefore we were interested in a comprehensive census of Class 2 types and subtypes
in the current set of complete bacterial and archaeal genomes. To this end, we
constructed sequence profiles for the effectors of all identified Class 2 subtypes (two
separate profiles were used for the variants V-U1, V-U2 and V-U5 and the V-U3 and
V-U4 variants were not included in the census because, in database searches, they
cannot be readily distinguished from transposon-encoded TnpB) and compared these
to the proteins encoded in the 4,961 completely sequenced prokaryotic genomes and
43,599 partial prokaryotic genomes available from the NCBI. This procedure should
detect virtually all instances of each effector, including highly diverged variants. The
neighborhoods of the respective genes were then examined for the presence of CRISPR
arrays and additional cas genes as previously described (Makarova et al., 2015).
The most striking observation is the dramatic dominance of type II, which is
represented in about 8% of bacterial genomes, among the Class 2 systems. Both type
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V and type VI are more than an order of magnitude less abundant, in agreement with
the expectation that the CRISPR-Cas types and subtypes remaining to be discov-
ered are rare variants (Makarova et al., 2015). An intriguing question is whether the
type II CRISPR-Cas system provides a substantial fitness advantage, perhaps being
more efficient in defense and/or incurring a lower cost, as compared to other Class
2 variants. Most of the Class 2 subtypes are represented in taxonomically diverse
bacteria and, furthermore, for type II and subtype V-A, the effector tree topologies
differ from the topology of the species tree (Chylinski et al., 2014; Dong et al., 2016).
These observations indicate that horizontal gene transfer might be the key process in
CRISPR-Cas evolution. It is notable, however, that the relatively abundant subtype
VI-B appears to be restricted to the phylum Bacteroidetes, perhaps reflecting some
unique aspect of the biology of these bacteria. Similarly, the V-U5 variant, which
contains an inactivated TnpB homolog, is limited to Cyanobacteria (see above), and
could be involved in a distinct cyanobacterial regulatory pathway. As has been pre-
viously noted (Makarova et al., 2011b; Makarova et al., 2015), and as is emphasized
by this present expansion of the diversity of Class 2 systems, apart from the identi-
fication of subtype V-A in mesophilic archaea in two instances, Class 2 systems are
unique to bacteria. The exclusion of Class 2 systems from archaea, particularly from
hyperthermophiles in which Class 1 systems are ubiquitous, implies that there is a
major functional distinction between the two classes of CRISPR-Cas systems, the
nature of which remains enigmatic.
B.4.2 Origins of Class 2 CRISPR-Cas Systems
Extending the previous hypothesis on the independent origins of the effectors in dif-
ferent types and subtypes of Class 2, we harness the findings on incomplete type
V loci to propose a more specific evolutionary scenario (Figure B-4). As discussed
above, at least 5 distinct variants within subtype V-U show a substantial degree of
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evolutionary stability and consistent association with CRISPR arrays, and typically
contain TnpB homologs that are intermediate in size between the compact transposon-
encoded TnpB proteins and the large Class 2 effectors (Figures B-2 and B-3b). These
groups of TnpB homologs might represent intermediate stages in independent paths
to the emergence of new CRISPR-Cas variants. The other CRISPR-tnpB associations
are not evolutionarily conserved and are likely to result from more or less random
insertions of tnpB genes next to CRISPR arrays; some of these loci could represent
the earliest stages of evolution of CRISPR-Cas systems.
All subtype V-U loci lack adaptation modules, suggesting that the first stage
of evolution of new Class 2 CRISPR-Cas involves the random insertion of a TnpB-
encoding element next to an orphan CRISPR array (Figure B-4). At the next step
of evolution, the association between CRISPR and a TnpB derivative would become
fixed in the microbial population, conceivably due to the emergence of a novel func-
tion, the exact nature of which remains to be understood. This would be accompanied
by an increase in the size of the protein via internal duplications and/or the inser-
tion of additional domains (Figure B-5). The final steps include further growth of
the effector protein, resulting in the typical bilobed structure and, in some cases,
its association with an adaptation module through recombination with a different
CRISPR-Cas locus (Figure B-4). Compatible with this scenario, the Cas1 proteins
of different subtypes of type II and of type V are homologous to different subtypes
of type I (Shmakov et al., 2015). That the adaptation modules came last is strongly
suggested by the fact that no subtype V-U loci contain the cas1 and cas2 genes,
whereas many of the loci containing typical, large effector proteins do.
The above scenario might be challenged with respect to the directionality of
evolution: the possibility could be considered that the transposon-encoded TnpB
actually evolved from Class 2 effectors. However, the scenario in which transposon-
encoded TnpB are the ancestral forms (Figure B-4) appears much more likely. First,
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Figure B-4: Possible routes of evolution for Class 2 CRISPR-Cas systems.
The figure depicts the three-step pathway of the evolutionary ‘maturation’ of type II,
type V and type VI CRISPR-Cas systems. The systematic and/or provisional gene
names are indicated below the respective ‘mature’ effector protein schematics and the
proposed intermediate forms of type V systems. The first step involves the random in-
sertion of a TnpB-encoding or insertion sequences Cas9-like protein B (IscB)-encoding
transposon or a higher eukaryotes and prokaryotes nucleotide-binding (HEPN) do-
main RNase-encoding gene next to a CRISPR cassette for type II, type V and type
VI systems, respectively. During the second step, the functional connection between
this protein and the CRISPR array is established and co-evolution begins, in particu-
lar, in the form of the accumulation of specific insertions that facilitate CRISPR RNA
(crRNA) binding. For type V systems, the intermediate forms that correspond to the
first and second step are identified as different type V-uncharacterized (V-U) vari-
ants. Additional components of the system could have originated during the second
step, such as trans-acting CRISPR RNA (tracrRNA) in the case of type II systems.
During the third step, further insertions lead to increased specificity of crRNA and
target binding, and enable interactions with accessory proteins, such as Csn2 for type
II-A and a protein with predicted transmembrane (TM) domains for type VI-B. The
adaptation module is only inserted into some of the class 2 CRISPR-cas loci during
the third step. TS, target site.
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TnpB-encoding transposons (autonomous and non-autonomous, including some that
have lost mobility) are far more abundant across a broad range of bacteria and archaea
than Class 2 CRISPR-Cas systems, which are relatively rare and limited in their
spread to a subset of bacterial phyla. Second, and perhaps more important, the Class
2 effectors are much larger and more complex than TnpB proteins, which makes
them unlikely ancestral forms. Third, the TnpB proteins are encoded in transposons
which, through their mobility, are well-suited to move into the vicinity of CRISPR
arrays; by contrast CRISPR-Cas systems lack active mobility mechanisms. Finally,
the observations reported here on the phylogeny of TnpB, in which the CRISPR-
associated variants are lodged among the transposon-encoded TnpB (Figure B-3a),
imply the ancestral status of TnpB.
Hypothetically, a similar scenario could apply to the type VI systems (Figure B-
4). A comprehensive database search for HEPN domain-containing proteins encoded
in the vicinity of CRISPR arrays failed to identify any evolutionarily stable config-
urations that might have been analogous to subtype V-U, while detecting numerous
members of the HEPN-containing Cas protein families, Csm6 and Csx1. Thus, it
seems possible that, during evolution, type VI systems recruited one of the HEPN-
containing Cas proteins, followed by duplication of the HEPN domain and further
expansion of the protein to the typical size of a Class 2 effector (Figure B-4). How-
ever, that type VI effectors directly originate from HEPN-containing toxins cannot
be ruled out; further screening of new genomes and metagenomes for likely ancestors
of the two-HEPN domain proteins should establish the origin of type VI effectors.
B.4.3 Amended Classification and Proposed Nomenclature
The systematic search for novel Class 2 CRISPR-Cas loci described here led to a
major expansion of the known diversity of these systems. Instead of the two types
and four subtypes included in the latest classification (Makarova et al., 2015), there
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Figure B-5: Functional diversity of the experimentally characterized Class
2 CRISPR-Cas systems. For each type of the class 2 CRISPR-Cas systems (and
two subtypes in the case of type V), a schematic of the complex between the effector
protein, the target, crRNA and, in the case of type II and type V-B systems, trans-
acting CRISPR RNA (tracrRNA), is shown. The position of the protospacer adjacent
motif (PAM) or the protospacer flanking site (PFS) is indicated by a red bar. The
small red triangles show the position of the cut, or cuts, in the target DNA or RNA
molecule. dsDNA, double-stranded DNA; ssRNA, single-stranded RNA.
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are now three types and at least 10 subtypes (Figure B-1). Some uncertainty remains
due to the lack of functional data on subtype V-U, but it appears likely that evolu-
tionary stable and apparently functional variants that are currently grouped into this
provisional subtype, particularly V-U3, will eventually be ‘upgraded’ to subtypes in
their own right. The functional characterization of V-U variants will provide a more
precise classification, although it is likely that many V-U loci do not encode typi-
cal, active CRISPR-Cas systems. Given the comprehensive character of the search
described here, we expect that the only new variants yet to be discovered will be
extremely rare or restricted in their spread to particular groups of prokaryotes that
are not adequately represented in current sequence databases. In fact, two new type
V CRISPR systems have been discovered in the genomes of uncultivated bacteria
(Burstein et al., 2017).
We believe that the expansion of the CRISPR-Cas classification calls for the
corresponding change to the nomenclature in which at least the experimentally char-
acterized effectors and their homologues are given new names that correspond to num-
bered Cas proteins (Figure B-2). Thus, the type V effectors would become Cas12a,
Cas12b and Cas12c, and those of type VI would become Cas13a, Cas13b and Cas13c
(numerical continuity with Cas9 is not possible because Cas10 and Cas11 are already
used for other proteins) (Makarova et al., 2015). The structure of Cas12b has been
solved in complex with crRNA, tracrRNA and the DNA template (Liu et al., 2016;
Yang et al., 2016), and it has been found to cleave target and non-target strands
with its RuvC-like nuclease domain. We currently refrain from renaming the puta-
tive subtype V-U effectors until functional evidence of a bona fide CRISPR response
for these effectors is reported, at which time we propose that they are referred to as
Cas12 proteins.
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B.5 Concluding Remarks
The genomic analysis presented here expands the diversity of Class 2 CRISPR-Cas
systems. In particular, the inclusion of non-autonomous CRISPR-Cas systems lacking
the adaptation module, combined with the search of expanded genomic and metage-
nomics databases, led to the discovery of three new subtypes which, together with
our previous analysis, increases the number of Class 2 subtypes from 4 to 10. Fur-
thermore, one of the new subtypes, V-U, at present, is a collection of diverse variants,
some of which are expected to become new subtypes once they have been function-
ally characterized. It seems especially notable that the newly discovered Class 2
systems all fall into the two previously defined subclasses, those that cleave the non-
target strand of the target dsDNA using a RuvC-like nuclease and those that attack
RNA targets with a two-HEPN RNase. The apparent repeated emergence of these
CRISPR-Cas varieties might reflect strict demands for protein structure to accom-
modate the crRNA and the target molecule, to which only a few protein folds are
conducive.
The new Class 2 variants show some unprecedented functional features, for
example, subtype V-A do not require a tracrRNA whereas other variants, such as
subtype VI-A (and likely all type VI systems) exclusively target RNA and appear to
induce a toxic response in cells. The subtype V-U is expected to show even more un-
usual properties. This functional diversity provides the potential for the development
of new, versatile genome editing and regulation tools. We provide indications that
different Class 2 types and subtypes independently originate from mobile elements
that encode diverse TnpB proteins (types II and types V) and from HEPN domain-
containing proteins (type VI) that ultimately originate from mRNA-cleaving toxins.
The remarkable diversity notwithstanding, we believe that the computational pipeline
applied here provides for a nearly exhaustive identification of Class 2 systems. What-
ever additional variants remain to be found, they will be either extremely rare or
127
confined to bacterial phyla that are currently unknown or poorly sampled. However,
as shown by the example of type VI, despite the rarity and/or narrow spread of such
variants, their biological features could be of major interest and potential value for
new applications.
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